Overcoming the plasma membrane barrier to improve the efficiency of therapeutic delivery to the cellular cytoplasm by Gadok, Avinash Kaur
 
 
 
 
 
 
 
 
 
Copyright 
by 
Avinash Kaur Gadok 
2017 
 
 
 
The Dissertation Committee for Avinash Kaur Gadok Certifies that this is the 
approved version of the following dissertation: 
 
 
Overcoming the plasma membrane barrier to improve the efficiency of 
therapeutic delivery to the cellular cytoplasm 
 
 
 
 
 
 
Committee: 
 
Jeanne C. Stachowiak, Supervisor 
Theresa O’Halloran 
Hugh D. C. Smyth 
Hsin-Chih (Tim) Yeh 
Janet Zoldan 
Overcoming the plasma membrane barrier to improve the efficiency of 
therapeutic delivery to the cellular cytoplasm 
 
 
by 
Avinash Kaur Gadok, BSEBE; MSE 
 
 
 
Dissertation 
Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 
 
The University of Texas at Austin 
May 2017 
 iv 
 
Acknowledgements 
I am very grateful to my advisor, Dr. Jeanne Stachowiak, for giving me the 
opportunity to join her lab from its very beginning, and for giving me the chance to 
complete such an innovative and exciting project. I would like to thank her for tirelessly 
sharing her technical expertise, for patiently helping me to develop my public speaking 
and writing skills, and for serving as a never-ending source of encouragement and 
enthusiasm during times of disappointment. Most importantly, I thank her for teaching 
me how to think critically, solve problems, and never give up. These are invaluable 
lessons that I will carry with me for the rest of my life, no matter my career path. 
I would also like to recognize the rest of my laboratory for their continued support 
and friendship over the last five years. In particular, I would like to especially thank our 
previous post-doctoral fellow, Dr. David Busch, for serving as an excellent mentor and 
source of inspiration to me throughout my graduate career. I am also very grateful to the 
senior scientist of the lab, Dr. Carl Hayden, for allowing me to conduct research with him 
in his laboratory at Sandia National Laboratories and for teaching me the art of optical 
design. I would also like to thank my partners in crime in the lab:  Wilton Snead, for 
endlessly indulging in bizarre conversations with me; Chi Zhao, for reminding me that 
life is good; and Andre DeGroot, for eating lunch with me. I would also like to 
acknowledge the other past and present members of the laboratory, including Christine 
Scheve, Dr. Wade Zeno, Zachary Imam, Ryan Woodall, and Samuel Mihelic, who have 
all been tremendous sources of support over the years, and who have made our lab a safe 
and enjoyable workplace for me. 
Further, I would also like to thank my undergraduate mentees, Katie Ha, Tu Cao, 
Brian Li, Tanner Rowley, and Amanda Meriwether, whose hard work and dedication 
 v 
 
have been instrumental to the success of my project. I would also like to recognize my 
collaborators, Dr. Hugh Smyth, Dr. Silvia Ferrati, and Dr. Eileen Lafer, as well as the rest 
of my committee members, Dr. Theresa O’Halloran, Dr. Tim Yeh, and Dr. Janet Zoldan, 
for their support and guidance on my work. 
I would also like to thank my friends outside of the lab, including Supreet Singh, 
Emily O’Toole, Dr. Maggie Rodgers, Dr. Rachel Buchanan, Salma Ayoub, and Daniela 
Santiesteban for their continued support, inspiration, and laughter over the years. Finally, 
I would like to thank my family, for encouraging the scientist within me from a very 
early age, for supporting me throughout the journey of graduate school, and for always 
believing in me.   
 vi 
 
Overcoming the plasma membrane barrier to improve the efficiency of 
therapeutic delivery to the cellular cytoplasm 
 
 
Avinash Kaur Gadok, Ph.D. 
The University of Texas at Austin, 2017 
 
Supervisor:  Jeanne C. Stachowiak 
 
Difficulties in controlling endocytosis limit the success of many nanoparticle-
based drug delivery strategies. Therefore, there is a need to both (i) introduce new 
mechanisms of therapeutic delivery that overcome the limitations of endocytic uptake, 
and (ii) gain better control of endocytosis by understanding its underlying mechanisms at 
a molecular level. Towards achieving efficient therapeutic delivery independently of 
endocytosis, I first report the development of targeted Connectosomes, cell-derived lipid 
vesicle materials that contain embedded connexons and are capable of forming functional 
gap junctions with cells. These materials encapsulated diverse molecular cargo, including 
dyes and drugs. These materials achieved efficient delivery of molecular cargo directly 
into the cytoplasm of specific populations of target cells, through interactions of 
embedded multi-functional, multi-domain transmembrane targeting proteins that target 
cell-specific receptors. By opening direct routes to the cytoplasm, targeted 
Connectosomes reduced the therapeutically effective dose (LD50) of doxorubicin for 
target cells by more than an order of magnitude in comparison to the unencapsulated 
drug, and by several orders of magnitude in comparison to conventional liposomal 
doxorubicin. These data illustrate the therapeutic importance of direct access to the cell 
 vii 
cytoplasm, and highlight the potential of gap junction-mediated cytoplasmic delivery to 
increase the effectiveness of diverse therapeutics. Towards furthering our basic 
biophysical understanding of the mechanisms that drive clathrin-mediated endocytosis, I 
then investigated the curvature sensing abilities of clathrin, a critical question limiting our 
understanding of how nanoparticles and other molecular cargo are internalized. In 
particular, my findings demonstrate that clathrin binds preferentially to highly curved 
membranes, suggesting a possible new explanation for clathrin’s early participation in 
endocytic vesicle formation. In sum, this work represents key steps towards improving 
the success of nanoparticle-based drug delivery strategies from both applied and 
fundamental standpoints. 
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Chapter 1:  Introduction 
How can therapeutics cross the plasma membrane barrier? 
To reach intracellular targets in the cytoplasm, therapeutics must be membrane 
permeable. Specifically, therapeutics must maintain solubility as they journey from the 
aqueous extracellular space, through the hydrophobic membrane environment, to their 
final destination in the aqueous cytoplasm1. 
Unfortunately, these stringent restrictions limit the design of therapeutics, as only 
select, highly membrane permeable molecules are able to cross the plasma membrane. 
Despite high membrane permeability, transport of these compounds into the cytoplasm is 
limited, even for the most widely used drugs2. For example, in order for one highly 
membrane permeable chemotherapeutic drug, doxorubicin3, to reach the cytoplasm, it 
must first associate with the outer leaflet of the plasma membrane, and then wait for a 
distinct trans-lipid bilayer flip-flop event to occur in order to reach the inner leaflet of the 
plasma membrane, before it can finally diffuse into the cytoplasm to reach its target4. In 
fact, in vitro studies have demonstrated that it takes on the order of several hours for 
doxorubicin to reach cytotoxic concentrations in the cytoplasm2. Further, increased 
membrane permeability also enhances association of therapeutics with multidrug efflux 
pumps. Therefore, the most highly membrane permeable drugs exhibit increased 
vulnerability to export by these pumps, limiting their accumulation inside the cell despite 
their ability to cross the plasma membrane barrier5. These hindrances necessitate large 
doses in order to achieve therapeutic efficacy, which in turn promote systemic toxicity 
toward healthy, off-target tissues6. 
The need for membrane permeability poses an even more substantially limit on 
the efficacy of highly hydrophilic drugs, which typically experience low rates of 
membrane transport. For example, nucleoside analogs such as gemcitabine and 
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cytarabine effectively inhibit DNA synthesis and are therefore promising cytotoxic 
agents. However, their therapeutic efficacy has been limited by insufficient cytoplasmic 
accumulation7. Similarly, the chemotherapeutic drug cisplatin also faces membrane 
solubility obstacles8. Therefore, the efficacy of each of these drugs could be improved by 
an efficient cytoplasmic delivery method. 
Owing to these membrane permeability restrictions, a disproportionate number of 
existing drugs exploit cell-surface proteins, which are accessible from outside the cell, 
such as ion channels and G-protein coupled receptors9.  In contrast, numerous 
intracellular targets remain undruggable10. Therefore, development of a strategy that 
bypasses the plasma membrane barrier could both enhance delivery of existing, 
membrane permeable drugs that are limited by inefficient cytoplasmic transport rates and 
export by multidrug efflux pumps, while also providing a new avenue for cytoplasmic 
delivery of entirely new types of therapeutic compounds, including membrane 
impermeable molecules. 
Nanoparticles enable drugs to cross the plasma membrane barrier 
In order to cross the plasma membrane barrier, therapeutics can be encapsulated 
within nanoparticles11, 12. For example, diverse membrane impermeable reagents can be 
encapsulated within the aqueous core of nanoparticle materials. Cells then internalize the 
nanoparticles via endocytosis13, and in a way, intracellular delivery of the nanoparticles is 
achieved. However, the internalized nanoparticles largely remain trapped in endosomes, 
which are membrane-bound compartments responsible for molecular sorting of 
internalized cargo14. Unable to escape from endosomes, nanoparticles face eventual 
degradation or export15. Therefore, delivery of the therapeutic into the cytoplasm is 
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limited, and the drug concentration required for therapeutic efficacy actually increases16, 
17. 
One of the first nanoparticles to be developed, doxorubicin loaded liposomes, best 
illustrates this dilemma. While these nanoparticles significantly reduced the systemic 
toxicity of doxorubicin3, in vitro studies found that encapsulating this drug into liposomes 
actually increased the therapeutically effective dose, or the median lethal dose (LD50), by 
an order of magnitude, likely due to the inability of the drug to reach the cytoplasm17. 
More recent studies have also confirmed the inefficiencies of endocytosis for achieving 
cytoplasmic release. For example, less than 2% of lipid-based nanoparticles used for 
siRNA delivery escaped from the endosome within 6 hours18, and more than 80% of 
mesoporous silica nanoparticles used for fluorescent dye delivery were exocytosed from 
cells after 6 hours15. Therefore, in sum, difficulties in controlling the endocytic process 
restrict the reliability of delivery strategies that rely upon this process for 
internalization19. 
Towards achieving cytoplasmic therapeutic delivery, diverse membrane-
disrupting agents have been developed in order to facilitate the escape of nanoparticles 
from endosomes20. These compounds include pH-sensitive polymers, and fusiogenic 
peptides and lipids20. In theory, these compounds rely upon the acidic environment of the 
endosome for activation, triggering the nanoparticle’s escape from the endosome and 
thereby facilitating cytoplasmic release21. For example, pH-sensitive polymers like 
poly(propyl acrylic acid) were used to efficiently disrupt eukaryotic membranes within 
narrowly defined pH ranges, suggesting promise as endosomal escape facilitators22. 
Further, the fusiogenic domain of hemagglutinin (HA), a virus fusion protein, and 
transactivator of transcription (TAT), the HIV fusion peptide, were used in combination 
to enhance in vitro intracellular protein delivery, providing proof-of-concept evidence of 
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the therapeutic potential of fusion peptides as endosomal escape agents23. Further, the 
fusiogenic lipid DOTAP was incorporated into synthetic liposomes also containing TAT 
to enhance delivery of DNA in A549 cells24. Finally, in some cases, incorporation similar 
of stimuli-responsive triggered-release compounds into nanoparticles21, 25 has reduced the 
therapeutically effective dose of particle-encapsulated doxorubicin to concentrations 
equivalent to the free drug21, 22, 25, 26. 
However, cytosolic release from the endosome remains limited despite these 
developments20, 27. In particular, many of these endosomal escape strategies do not 
facilitate sufficient drug release, or fail when extended to other applications20. For 
example, in the above example where HA and TAT were used for intracellular protein 
delivery, more than 99% of the proteins remained trapped in endocytic vesicles, despite 
inclusion of the fusion peptides20, 23 Additionally, the DOTAP liposomes discussed above 
failed to enhance delivery of DNA in other cell types20, 24. In light of these persistent 
limitations, a new delivery route that bypasses endocytic pathways entirely has the 
potential to dramatically improve therapeutic efficacy for both membrane permeable and 
impermeable drugs. 
Gap junctions provide direct access to the cytoplasm 
Cells naturally circumvent the plasma membrane barrier by relying upon gap 
junctions to deliver small molecules to each other. Gap junctions are formed from a 
family of 21 different connexin proteins, which range in molecular weight from 25 to 60 
kDa28. Connexin proteins hexamerize into either homomeric or heteromeric connexon 
hemichannels, depending on the types of connexins involved29. Estimates for the 
connexon pore diameter based on atomic force microscopy and electron diffraction range 
 5 
from 15 – 45 Å, while calculations based on the size of molecules known to be gap 
junction permeable approximate the pore diameter to be between 8 – 16 Å30. 
To form a complete gap junction, connexons present on the plasma membrane 
pair with connexons present on neighboring cell membranes, establishing a direct path 
that connects the cytoplasm of the cells. Cells use gap junctions to exchange diverse 
molecular cargo up to 1 kDa in size, including metabolites, second messengers, and 
peptides31. Gap junctions are expressed by nearly every cell type in the body, and the 
exchange of these molecules is critical for diverse cellular processes, including the 
maintenance of homeostasis, cell growth and differentiation, and coordination of 
electrical signaling that occurs in neurons, cardiac cells, and smooth muscle cells28, 29, 32. 
Gap junctions are emerging as a promising new therapeutic frontier 
Although gap junctions are traditionally considered to be facilitators for exchange 
of signaling molecules between cells, they are emerging as a promising new frontier for 
therapeutic drug delivery. For example, in addition to their ability to transfer natural 
signaling molecules between cells, gap junctions also facilitate transfer of drugs, through 
a phenomenon known as the bystander effect. Through this effect, therapeutics which 
reach the cytoplasm of one cell are able to access the cytoplasm of neighboring cells 
through the gap junctions that connect the cells. Exchange of drugs through this 
phenomenon enhances the efficacy of numerous therapeutics, including paclitaxel, 
doxorubicin33, gemcitabine34, etoposide33, and others35, demonstrating the potential 
importance of gap junctions as therapeutic conveyers. Further, it has recently been 
demonstrated that the presence of gap junction channels in exosomes underlies their 
ability to deliver siRNA, further suggesting the therapeutic potential of gap junctions36.  
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Taken together, these recent findings suggest that a therapeutic delivery approach 
that depends on gap junctions could provide an efficient new mode of drug transport. In 
particular, lipid vesicles that contain embedded gap junction hemichannels could come 
together with cellular hemichannles to form full gap junction channels with cells, opening 
a direct route to the cytoplasm that is independent of endocytosis. In this way, gap 
junction vesicles could both enhance delivery of existing, membrane soluble drugs, while 
also providing a new route for cytoplasmic delivery of hydrophilic molecules. 
Plasma membrane blebbing enables production of gap junction vesicles 
Despite the emerging evidence for gap junctions to act as therapeutic conveyers, 
gap junction vesicles have not been previously used for therapeutic delivery purposes. 
Although basic biological studies have demonstrated the formation of functional gap 
junctions between cells and synthetic vesicles containing reconstituted connexins37, 
therapeutic application of these vesicles has been limited, due perhaps to challenges in 
purifying connexin proteins, and in inserting the connexin proteins into membranes in 
functional orientations. 
However, plasma membrane blebs, also known as plasma membrane vesicles, are 
cell-derived materials that offer the potential to overcome these limitations. These 
vesicles are produced when the cytoskeleton’s attachment to the plasma membrane is 
disrupted, and are produced naturally during certain cellular processes such as cell 
motility or cytokinesis38, as well as a result of chemical induction39. 
In particular, biophysical studies on plasma membrane vesicles have shown that 
transmembrane proteins maintain their function and orientation when they are embedded 
in these vesicles40. Further, plasma membrane vesicles have recently emerged as 
potentially attractive therapeutic materials41. Exosomes, cell-derived vesicles that are 
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released from cells when multivesicular bodies fuse to the plasma membrane42, are 
another type of cell-derived material with emerging therapeutic potential43. 
However, plasma membrane vesicles were used for these studies, due to several 
advantages arising from the differences in origin between these two types of vesicles. 
Primarily, since protein trafficking to the plasma membrane is well understood, 
expression of transmembrane proteins at the plasma membrane can be easily controlled. 
Therefore, incorporation of these transmembrane proteins into plasma membrane vesicles 
is relatively straightforward, since they are derived directly from the plasma membrane39. 
In contrast, exosomes are derived from cell’s endosomal membrane system. Precise 
understanding of how proteins are sorted in endosomes in order to arrive in exosomes 
remains unclear42, and because of this, controlled incorporation of specific proteins into 
exosomes remains a challenge. 
Connectosomes for direct molecular delivery to the cellular cytoplasm 
Inspired by the natural ability of gap junctions to directly access the cytoplasm, in 
Chapter One, I report the development of Connectosomes, cell-derived lipid vesicle 
materials that contain embedded connexons and are capable of forming complete gap 
junctions with cells44. Specifically, by harvesting plasma membrane blebs from donor 
cells that overexpressed connexin 43 proteins with a C-terminal YFP modification 
(Cx43-YFP), I produced cell-derived lipid vesicle materials with embedded connexin 43-
YFP connexons, termed Connectosomes. These materials encapsulated diverse molecular 
cargo, including dye and drugs. By opening direct routes to the cytoplasm, 
Connectosomes achieved efficient delivery of molecular cargo to the cytoplasm in a gap 
junction-dependent manner. Further, I found that Connectosomes reduced the 
therapeutically effective dose (LD50) of doxorubicin by more than an order of magnitude 
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in comparison to the unencapsulated drug, and by several orders of magnitude in 
comparison to conventional liposomal doxorubicin. These data illustrate the therapeutic 
importance of direct access to the cell cytoplasm, and highlight the potential of gap 
junction-mediated cytoplasmic delivery to increase the effectiveness of diverse 
therapeutics. 
Targeted delivery approaches increase the specificity of therapeutic delivery 
While Connectosomes provide a promising new route for the delivery of 
therapeutics to the cytoplasm, the lack of specificity in this approach is a key roadblock 
limiting its therapeutic relevance. In particular, due to the ubiquitous29 nature of connexin 
proteins, the translational potential of Connectosomes is restricted by the possibility of 
nonspecific drug interactions occurring between the vesicles and healthy, off-target 
tissues. 
Towards achieving selective therapeutic delivery, targeting moieties have been 
incorporated into the surfaces of nanoparticles. By biochemically recognizing tumor-
specific cell surface receptors, these targeting agents promote preferential interaction of 
the nanoparticles with target tumor cells. Diverse targeting ligands, including various 
antibodies, organic compounds, and peptides, have been employed to direct both 
synthetic and cell-derived nanoparticles to specific populations of target cells in this 
way45-48. 
Despite the increased specificity these approaches yield, their ability to direct 
nanoparticles to specific populations of target cells in more complex applications remains 
inherently limited due to their dependence on complex chemical conjugation processes 
that are often incompatible with the maintenance of transmembrane protein function. To 
work around these limitations, our group and others have developed alternative targeting 
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strategies, which employ the cell’s own machinery to incorporate targeting ligands into 
cell-derived vesicles49-54. In particular, recent work from our group has harnessed the 
cell’s ability to manufacture complex, sophisticated macromolecules, by engineering a set 
of multi-functional, multi-domain transmembrane targeting ligands, which selectively 
increase cell-derived vesicle binding to target cells54. 
Targeted Connectosomes achieve therapeutic delivery to specific cell populations 
Towards achieving targeted, gap junction-mediated cytoplasmic therapeutic 
delivery, in Chapter Two, I report the development of targeted Connectosomes. 
Specifically, to enable delivery of therapeutic molecules directly into the cytoplasm of 
specific populations of target cells, I incorporated multi-functional, multi-domain 
transmembrane targeting proteins into the Connectosomes. In particular, by extracting 
plasma membrane blebs from engineered donor cells which co-express connexin 43-YFP 
and a targeting protein, we produced Connectosomes which also contained embedded 
copies of the targeting protein. I used a previously designed targeting protein that was 
comprised of five domains: the intracellular and transmembrane domains of transferrin 
receptor, an mRFP fluorophore domain, an intrinsically disordered linker domain 
comprised of the first 289 amino acids of AP180, and an affinity domain. Here, the 
affinity domain consisted of a single domain camelid GFP nanobody, which is a targeting 
ligand that specifically recognizes GFP, and can therefore be used to precisely target cells 
on the basis of their expression of GFP-tagged plasma membrane receptors. My results 
show that targeting selectively enhances Connectosome binding to target cells by more 
than an order of magnitude, compared to off-target cells. Targeted Connectosomes 
selectively deliver dye to the cytoplasm of target cells, three times as efficiently as to off-
target cells. Further, using targeted Connectosomes to deliver doxorubicin reduces the 
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therapeutically effective dose (LD50) by a factor of 2 for target cells, compared to off-
target cells. Illustrating the potential of targeted Connectosomes to serve as efficient 
vehicles for targeted molecular delivery of chemotherapeutics and other diverse drugs to 
the cell cytoplasm, this work represents a key step towards realizing the therapeutic 
potential of gap junction-mediated therapeutic delivery systems. 
Clathrin-mediated endocytosis  
While the majority of my thesis work has been focused on developing an alternate 
strategy that depends on gap junctions for therapeutic delivery rather than endocytosis, 
there is also value in approaching the problem of how to efficiently deliver drugs to the 
cytoplasm from a more fundamental standpoint. As mentioned above, difficulties in 
controlling endocytosis limit the success of many nanoparticle-based drug delivery 
strategies19. In order to effectively control and exploit endocytosis for optimal uptake of 
therapeutics, it is critical to first understand this process at a mechanistic level. Therefore, 
furthering our basic biophysical understanding of the mechanisms that drive clathrin-
mediated endocytosis is important for guiding improved treatment of disease. 
Membrane curvature sensing plays an important role in the nucleation of 
endocytic vesicles, which is the first step in endocytosis.  In particular, by binding 
preferentially to curved regions of the plasma membrane, adaptor proteins involved in 
endocytic vesicle nucleation essentially determine where these vesicles will form, thereby 
controlling which cargo molecules are internalized by the cell. These adaptor proteins 
bind preferentially to regions of high membrane curvature in two ways:  through (i) BAR 
domains, inherently curved domains which can scaffold curved membranes, and/or 
through (ii) amphipathic helices, which insert into lipid packing defects that are present 
on the surfaces of highly curved membranes55-57. 
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Understanding which proteins sense curvature, and the length scale over which 
this sensitivity exists, is a critical for understanding the dynamics of endocytosis. For 
example, amphipathic helices and BAR domains enable proteins to sense curvature over 
nanometer-scale membrane regions, implying that this type of sensitivity is very 
important early in endocytosis55-57. However, if clathrin were to act as a curvature sensor, 
it could potentially sense curvature over tens-of-nanometer-scale membrane regions, 
which would imply that curvature sensing that occurs throughout the formation of 
endocytic vesicles. 
Therefore, in Chapter Three, I investigate the curvature sensitivity of clathrin. 
Adaptor proteins, which bind to the membrane and to clathrin, are responsible for the 
biochemical recruitment of clathrin to endocytic structures. However, the physical cues 
that influence clathrin’s recruitment remain debated. In particular, while both scaffolding 
adaptor proteins such as epsin, and endophilin, and amphiphysin bind preferentially to 
regions of high membrane curvature, it remains unknown whether clathrin triskelia 
themselves possess the ability to sense membrane curvature and bind preferentially to 
curved structures. 
To address this question, I isolated clathrin’s curvature sensing ability in the 
absence of adaptor proteins by using recombinant, histidine-tagged clathrin that is 
engineered to bind directly to Ni-NTA-containing membranes. To examine clathrin 
binding to these membranes, I used a quantitative fluorescence intensity-based approach 
in which vesicles were tethered to a passivated surface and incubated with clathrin 
triskelia at a specified concentration.  
Using particle detection software and single-molecule calibrations to determine 
the brightness of each vesicle and the brightness of the protein colocalized to each 
vesicle, I quantified the curvature of each individual vesicle as well as the corresponding 
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number of bound clathrin triskelia. My results demonstrate that clathrin binds 
preferentially to membranes of higher curvature. Specifically, when incubated with the 
same concentration of clathrin triskelia, vesicles with an average diameter of 30 nm 
recruit ten times as many clathrin triskelia per membrane surface area in comparison to 
vesicles with an average diameter of 165 nm. Further, using the Boltzmann equation, we 
have determined how the binding energy released as clathrin triskelia bind to vesicles 
depends on vesicle curvature. Our ongoing work continues to map the distribution of 
bound triskelia over vesicles with a range of different curvatures and to improve the 
statistical model from which the curvature dependence of binding energy can be derived. 
These findings provide fundamental insight into the process by which clathrin is 
recruited to highly curved membranes during clathrin-mediated endocytosis. In 
particular, it has previously been thought that only adaptor proteins sense curvature, 
while clathrin’s role is simply to concentrate coated vesicle components and drive 
curvature58. However, our findings suggest that clathrin triskelia themselves are likely 
involved in sensing curvature. One possible role of clathrin as a curvature sensor could be 
to limit assembly of clathrin-coated vesicles only to groups of membrane-bound adaptor 
proteins located in regions of high membrane curvature. 
More broadly, our data suggests that the highly sequential model of clathrin-
coated vesicle assembly, in which adaptors arrive at membranes first and are then 
followed by clathrin, could be over simplified. Specifically, our findings suggest that 
recruiting a critical nucleus of clathrin triskelia could be an early event that depends on 
membrane curvature. This speculation is consistent with the recent finding by the 
Kirchhausen lab, which was based on studies in live cells and showed that recruitment of 
clathrin is one of the earliest events to occur in the formation of a clathrin-coated 
vesicle59.   
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Chapter 2:  Connectosomes for Direct Molecular Delivery to the 
Cellular Cytoplasm1 
Abstract 
Transport of biomolecules, drugs, and other reagents across the cell’s plasma 
membrane barrier is an inefficient and poorly controlled process, despite its fundamental 
importance to biotechnology, cell biology, and pharmaceutics. In particular, insufficient 
membrane permeability frequently limits the accumulation of drugs and reagents in the 
cytoplasm, undermining their efficacy. While encapsulating drugs in particles increases 
uptake by cells, inefficient release of drugs from these particles into the cytoplasm 
ultimately limits drug efficacy. In contrast, gap junctions provide a direct route to the 
cytoplasm that bypasses the plasma membrane. As transmembrane channels that 
physically connect the cytoplasm of adjacent cells, gap junctions permit transport of a 
diverse range of molecules, from ions and metabolites to siRNA, peptides, and 
chemotherapeutics. To utilize gap junctions for molecular delivery we have developed 
Connectosomes, cell-derived lipid vesicles that contain functional gap junction channels 
and encapsulate molecular cargoes.  Here we show that these vesicles form gap junction 
channels with cells, opening a direct and efficient route for the delivery of molecular 
cargo to the cellular cytoplasm. Specifically, we demonstrate that using gap junctions to 
deliver the chemotherapeutic doxorubicin reduces the therapeutically effective dose of 
the drug by more than an order of magnitude. Delivering drugs through gap junctions has 
                                                
1 This chapter is adapted from the publication:  A. K. Gadok, D. J. Busch,  S. Ferrati, B. Li, H. D. C. 
Smyth, J. C. Stachowiak, “Connectosomes for Direct Molecular Delivery to the Cellular Cytoplasm,” 2016, 
Journal of the American Chemical Society. 138(39), 12833-12840. I performed all of the experiments and 
wrote the manuscript.			
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the potential to boost the effectiveness of existing drugs such as chemotherapeutics, while 
simultaneously enabling the delivery of membrane-impermeable drugs and reagents. 
Introduction 
Membrane permeability is a fundamental requirement for biomolecules, drugs, 
and reagents that act on intracellular targets. To cross the plasma membrane, molecules 
must be soluble in both the hydrophobic membrane environment and in the aqueous 
cytosol1. Meeting these requirements while maintaining activity frequently over-
constrains molecular design. For example, the effectiveness of chemotherapeutic drugs 
with marginal membrane permeability, such as gemcitabine, cytarabine2, or cisplatin3, is 
limited by poor accumulation in the cytoplasm. Even highly membrane permeable drugs, 
such as doxorubicin4, have limited transport rates across the plasma membrane5, such that 
therapeutically effective doses are large, promoting systemic toxicity6. Further, increasing 
the membrane permeability of drugs also frequently increases their vulnerability to export 
by multidrug efflux pumps7, restricting their accumulation in the cytoplasm. In sum, 
crossing the plasma membrane is a substantial challenge that limits the performance of 
even the most successful drugs. This challenge is among the primary reasons that easily 
accessible cell-surface proteins, such as G-protein coupled receptors and ion channels, 
are the targets of the majority of existing drugs8, while many potentially valuable 
intracellular targets have not been successfully exploited9.  
Towards overcoming the challenge of crossing the plasma membrane, drugs are 
frequently encapsulated within nanoparticle materials10,11. Loading doxorubicin into 
liposomes was one of the earliest uses of nanoparticles for drug delivery. This approach 
substantially reduced the drug’s systemic toxicity4, illustrating the potential of 
nanoparticles to improve drug delivery. However, upon reaching tumor cells, 
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nanoparticles enter cells through endocytosis,12 frequently becoming trapped in the 
endosomal lumen, which is topologically equivalent to the extracellular milieu13. 
Inefficient endosomal escape leads to nanoparticle degradation and export14, limiting the 
efficiency of cytoplasmic delivery15 and increasing the drug concentration required to kill 
cancer cells16. For example, in in vitro studies the therapeutically effective dose, i.e. the 
median lethal dose (LD50), of doxorubicin increases by an order of magnitude when the 
drug is encapsulated within liposomes16.  
To facilitate endosomal escape, several strategies have been developed that 
incorporate pH-sensitive polymers17, peptides18, and other compounds19 into 
nanoparticles. These membrane-disrupting agents are activated by the acidic endosomal 
environment, leading to intracellular release of encapsulated drugs20. Along with other 
triggered-release strategies21, these advancements have reduced the therapeutically 
effective dose of particle-encapsulated doxorubicin to concentrations equivalent to the 
free drug17,19-21. Further, in some cases, endosomal release strategies have helped to 
overcome multidrug efflux processes22, and coupling endosomal release to materials with 
high drug-carrying capacities, such as silica protocells23,24 or laponite disks25, has further 
reduced the therapeutically effective dose of particle-encapsulated doxorubicin to levels 
below that of the free drug. 
Despite these substantial advancements, delivery approaches that rely upon 
endocytosis to achieve intracellular release remain constrained by the difficulty of 
controlling the process26 and by the variability of the endosomal environment, which 
frequently limits release27,28. For example, more than 80% of mesoporous silica 
nanoparticles are exocytosed from cells after 6 hours14, leaving a limited window of time 
for intracellular drug release. In addition, less than 2% of lipid nanoparticles taken up by 
endocytosis escape from the endosome within 6 hours29. In light of these persistent 
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limitations, a new delivery route that bypasses endocytic pathways entirely has the 
potential to dramatically improve therapeutic efficacy. 
By providing direct access to the cytoplasm, the cellular gap junction network 
suggests a means of circumventing the plasma membrane barrier. Cells exchange 
molecular cargo including metabolites, second messengers, peptides30, and siRNA with 
their neighbors using gap junctions31. The proteins that form gap junctions, connexins, 
assemble into connexons. These hexameric pores are present on the cellular plasma 
membrane. When connexons from two neighboring cells meet, they form a complete gap 
junction channel, enabling molecules to move from the cytoplasm of one cell to the next 
by diffusing through the channel. Through a phenomenon known as the bystander effect, 
cells share drugs via gap junctions. This effect enables drug penetration in tumors32 and 
promotes the efficacy of diverse chemotherapeutics, including doxorubicin33, etoposide33, 
paclitaxel33, gemcitabine34, and others35. Inspired by the ability of gap junctions to directly 
access the cytoplasm, here we report the development of Connectosomes, connexon-
containing cell-derived lipid vesicle materials that form functional gap junctions with 
cells. Using these materials, we demonstrate gap junction-dependent delivery of 
molecular cargo into the cytoplasm. Our results indicate that this approach reduces the 
therapeutically effective dose (LD50) of doxorubicin by more than an order of magnitude 
in comparison to the free drug, and by multiple orders of magnitude in comparison to 
liposomal doxorubicin. These results demonstrate the potential of gap junction-mediated 
intracellular delivery to enhance the effectiveness of diverse therapeutics. 
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Results and Discussion 
Connectosome formation and loading 
Connexons have previously been reconstituted in synthetic vesicles for basic 
biological studies, demonstrating formation of functional junctions between vesicles and 
cells36. However, these vesicles have not been pursued for therapeutic purposes, likely 
due to technical difficulties including (i) purifying sufficient quantities of transmembrane 
proteins, (ii) inserting the proteins into vesicles, and (iii) controlling their orientation in 
the membrane. To overcome these limitations, we used the process of plasma membrane 
blebbing to harvest Connectosomes directly from donor cells that overexpressed gap 
junctions. Plasma membrane blebs, also known as plasma membrane vesicles, form when 
attachments between the plasma membrane and the cytoskeleton are disrupted37 during 
cellular processes including cell motility and cytokinesis37, and maintain the directional 
insertion and function of transmembrane proteins38. Plasma membrane blebs have 
frequently been used as biophysical models, and have recently emerged as potentially 
attractive materials for therapeutic applications39,40. Notably, exosomes, which are cell-
derived vesicles released from cells by fusion of multivesicular bodies to the plasma 
membrane41  have also recently emerged as potential drug delivery vehicles42 Plasma 
membrane blebs and exosomes differ in several significant ways including the membrane 
system they originate from and  the extent to which their transmembrane protein content 
can be controlled. Specifically, blebs are derived directly from the plasma membrane 
system, while exosomes are derived from the cell’s endosomal membrane system. Since 
protein traffic to the plasma membrane is well understood, conventional protocols can be 
used to express proteins at the plasma membrane surface, resulting in their incorporation 
into blebs43. In contrast, understanding of how protein sorting in the endosomal system 
leads to selection of proteins by the exosomal pathway is still emerging41  making the 
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incorporation of specific protein constituents in exosomes difficult to predict and control. 
Nonetheless, a recent report suggests that connexins may contribute to the ability of 
exosomes to transfer their native internal contents to cells44 While this study did not 
investigate the use of connexins to deliver drugs, these findings are consistent with the 
idea that cell-derived particles with well-controlled connexin expression could provide an 
effective new mode of drug delivery. By extracting blebs from donor cells that 
overexpressed connexin 43 proteins with a C-terminal YFP modification (Cx43-YFP), 
we produced cell-derived lipid vesicle materials with embedded connexin 43-YFP 
(Figure 2.1a-e). Over 90% of these Connectosomes contained connexin 43-YFP at levels 
detectable by fluorescence imaging. The Connectosomes ranged in diameter from 4 to 
more than 20 µm, with an average diameter of 10 µm (Figure 2.1j). Notably, 
Connectosomes can be extruded to reduce their diameter to around 100 nanometers. 
Based on quantitative measurements of YFP fluorescence, we determined that the 
average Connectosome contained over 400,000 connexons, which cumulatively covered 
nearly 10% of the vesicle surface (Figure 2.1k).
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Figure 2.1: Connectosomes loaded with molecular cargo were harvested from donor cells. 
Confocal fluorescence images. (a), Schematic of the Connectosome production process. (b-d), Plasma 
membrane blebs were extracted from donor cells overexpressing connexin 43-YFP (arrows) to produce 
Connectosomes, cell-derived lipid vesicle materials with embedded connexin 43-YFP connexons. (e), 
Multiple Connectosomes in a single field of view. (f-h), Plasma membrane blebs (arrows) were extracted 
from donor cells treated with CRO dye to produce CRO dye-loaded Connectosomes. (i), Multiple CRO 
dye-loaded Connectosomes in a single field of view. (j), Histogram of Connectosome diameters. 154 
Connectosomes were measured. (k), A calibration curve of YFP fluorescence was generated to determine 
the YFP content of the Connectosomes. All scale bars 20 µm except for (d) and (h), which are 2 µm. 
Images in (c) and (g) intentionally saturated to show Connectosome formation. 
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Connectosomes contained functional gap junction channels 
To test the functionality of connexon channels embedded in Connectosomes, we 
examined the ability of the channels to open and close in the absence and presence of 
calcium. Specifically, it is well established that calcium causes unpaired connexons to 
close, obstructing the passage of molecules45-47. However, in the absence of calcium, 
connexons undergo a conformational change that causes them to open, allowing small 
molecules to diffuse through them45. We began by examining the ability of connexons to 
open upon calcium removal, releasing dye encapsulated within the Connectosomes. To 
load Connectosomes with the dye we treated the donor cells with calcein red-orange 
(CRO) acetomethoxy (AM) prior to extracting membrane blebs (Figure 2.1f-i). CRO AM 
diffuses freely across the plasma membrane. However, when the dye reaches the 
cytoplasm, intracellular esterases hydrolyze the acetomethoxy group. The resulting CRO 
dye molecule is membrane impermeable, trapped inside of the cell and permeable only to 
gap junctions (Figure 2.1f)48. In the presence of calcium, the Connectosomes retained the 
CRO dye (Figure 2.2a, top). However, when calcium was removed by addition of EGTA 
and EDTA chelators, the dye was released from 87% of the Connectosomes and retained 
by only 13%, demonstrating that the connexons opened (Figure 2.2a, bottom; b-c).
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Figure 2.2:  Continued on next page. 
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Figure 2.2: Connectosomes contained functional connexons. Confocal fluorescence images. (a), 
Connectosomes retained CRO dye in a solution of 2 mM Ca2+ (top), but released dye when Ca2+ was 
removed (bottom). (b), Percentage of Connectosomes releasing dye +/- Ca2+. The error bars represent the 
standard deviations of 3 independent trials; at least 54 Connectosomes analyzed per trial. (c), Schematic 
illustrating connexon-dependent molecular exchange. (d), Plasma membrane blebs derived from MDA-
MB-231 cells retained CRO dye in a solution of 2mM Ca2+ (top), as well as when Ca2+ was removed 
(bottom). (e), Percentage of MDA-MB-231 GPMVs releasing dye +/- Ca2+. The error bars represent the 
standard deviations of 3 independent trials, at least 36 Connectosomes analyzed per trial. (f), 
Connectosomes excluded Atto 594 in 2 mM Ca2+ (top), but filled with dye when Ca2+ was removed 
(bottom). (g), Percentage of Connectosomes including dye +/- Ca2+. The error bars represent the standard 
deviations of 3 independent trials, at least 51 Connectosomes analyzed per trial. (h), The Atto 594 dye 
within Connectosomes (top) was photobleached (middle) in the absence of Ca2+. The Connectosomes 
refilled with dye within 75 seconds after the laser illumination was stopped (bottom). Scale bars: 2µm. 
Asterisks represent statistically significant differences (two-tailed t-test, p < 0.001). 
To further illustrate the dependence of dye release on the presence of functional 
connexons in the Connectosomes, we formed CRO dye-loaded plasma membrane blebs 
from MDA-MB-231 donor cells. MDA-MB-231 cells express low levels of connexin 43 
and exhibit defective connexin trafficking and gap junction formation, resulting in 
substantially reduced gap junction intercellular communication49. In the presence of 
calcium, 91% of MDA-MB-231 blebs retained the dye (Figure 2.2d, top). When calcium 
was removed by addition of EGTA and EDTA chelators, 85% of the MDA-MB-231 
blebs continued to retain the dye, in comparison to only 13% of Connectosomes, 
demonstrating that the dye release was dependent on the presence of functional 
connexons (Figure 2.2d, bottom; e).  
Next, we developed an exogenous method of loading, in which molecular cargo 
was encapsulated after Connectosome formation.  Specifically, we added a water-soluble 
dye with little or no membrane permeability, Atto 594, to the solution surrounding pre-
formed Connectosomes. In the presence of calcium, the Connectosomes excluded the 
dye, demonstrating that connexons remained closed (Figure 2.2f, top). However, when 
calcium was removed by addition of EGTA and EDTA chelators, 99% of the 
Connectosomes filled with dye, demonstrating that the connexons opened (Figure 2.2f, 
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bottom; g). Similar results were also obtained for Connectosomes loaded with Atto 488 
dye using an identical protocol (Supporting Information Figure 2.5). Atto 488 has been 
reported to have no significant interaction with membranes50, making the dye almost 
perfectly membrane impermeable.  
Finally, to probe the timescale of diffusion through open connexons, we 
photobleached Atto 594 dye loaded within the Connectosomes. In the absence of 
calcium, the Connectosomes refilled with dye within 75 seconds after photobleaching 
(Figure 2.2h). Together, these results demonstrate two distinct modes of loading 
Connectosomes and demonstrate that Connectosomes contain multiple functional 
connexons, capable of opening and closing to enable rapid molecular exchange with the 
external environment. Further, comparison to MDA-MB-231 blebs suggests that 
molecular exchange is connexon-dependent. 
Connectosomes delivered molecular cargo to the cellular cytoplasm 
Having established the functionality of the connexons, we next examined the 
ability of the Connectosomes to deliver molecular cargo into the cellular cytoplasm 
(Figure 2.3a). While the presence of calcium keeps unpaired connexons closed45, 
complete channels form and open when two unpaired connexons on the surfaces of 
neighboring cells meet, even in the presence of physiological levels of extracellular 
calicium51,52. To test the ability of Connectosomes to form gap junctions with cells, we 
prepared a confluent monolayer of recipient HeLa cells. CRO dye-loaded Connectosomes 
were prepared as described above (Figure 2.1f-i) and incubated with the recipient cells. 
Imaging the recipient cells after 2 hours revealed the intracellular accumulation of dye 
(Figure 2.3b, Supporting Information Figure 2.6). To quantify the CRO dye delivery, we 
measured the relative fluorescence intensity of the cell populations using flow cytometry 
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(Figure 2.3c-e). Exposure to CRO dye-loaded Connectosomes increased the average 
fluorescence of the recipient cells by a factor of 6, in comparison to background 
fluorescence from untreated cells (Figure 2.3d, Supporting Information Figure 2.6). 
Additionally, we drew a threshold at the peak of the fluorescence histogram for cells 
receiving dye-loaded Connectosomes (Figure 2.3c). The average percentage of cells with 
fluorescence greater than this threshold increased from less than 4% for untreated cells to 
over 51% for cells exposed to dye-loaded Connectosomes (Figure 2.3e). To demonstrate 
that the CRO dye delivery was gap junction-dependent, we used carbenoxolone53 (CBX), 
a drug which blocks the coupling of connexons, to inhibit the formation of gap junctions 
between Connectosomes and recipient HeLa cells. Repeating the dye delivery experiment 
in the presence of this gap junction inhibitor significantly decreased the average recipient 
cell fluorescence, illustrating that dye delivery was dependent on the assembly of gap 
junction channels between the Connectosomes and the cells (Figure 2.3c-e, Supporting 
Information Figure 2.6). CBX treatment did not completely eliminate the increase in 
fluorescence of the recipient cells upon exposure to dye-loaded Connectosomes, likely 
because CBX is not a complete inhibitor of gap junction communication53 and because 
CBX itself somewhat increases the fluorescence of the recipient cells, in the absence of 
Connectosome treatment (Figure 2.3c-e, Supporting Information Figure 2.7). 
To further demonstrate the gap junction-dependence of the CRO dye delivery, we 
repeated the same experiment as above, using plasma membrane vesicles that lacked a 
significant concentration of functional connexons (Supporting Information Figure 2.8). 
Specifically, we formed CRO dye-loaded plasma membrane vesicles from A549 cells, 
which are known to have low levels of connexin expression and gap junctional 
communication54. We incubated these connexon-lacking plasma membrane vesicles with 
recipient HeLa cells, and measured the relative recipient cell fluorescence using flow 
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cytometry (Supporting Information Figure 2.8). We found that the fluorescence signal 
from cells exposed to CRO dye-loaded A549 vesicles was more than an order of 
magnitude less than the average fluorescence signal from cells exposed to 
Connectosomes. Collectively, these results demonstrate gap junction-dependent delivery 
of molecular cargo using Connectosomes.
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Figure 2.3: Connectosomes delivered dye to the cellular cytoplasm. Brightfield and confocal 
fluorescence images. (a), Schematic. (b), Two Connectosomes (arrows) delivering CRO dye to the cellular 
cytoplasm. (c), Flow cytometry histograms showing CRO dye fluorescence for each recipient cell 
condition. The dotted line, drawn at the peak of the fluorescence histogram for cells receiving CRO dye-
loaded Connectosomes, is used as a threshold in (e). Each curve represents 3 independent, concatenated 
trials, 10,000 cells analyzed per trial. (d), Average recipient cell fluorescence for each condition. The error 
bars represent the standard deviations of 3 independent trials, 10,000 cells analyzed per trial. (e), 
Percentage of cells with fluorescence values above the threshold drawn in (c). The error bars represent the 
standard deviations of 3 independent trials, 10,000 cells analyzed per trial. Legend in (c) applies to (d-e). 
Scale bar: 10 µm. Asterisks represent statistically significant differences (two-tailed t-test, p < 0.04 (d) and 
p < 0.01 (e)). Image of Connectosome in (b) intentionally saturated to show intracellular dye accumulation. 
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Connectosomes increased the therapeutic efficacy of doxorubicin 
Next, we investigated the use of Connectosomes to deliver the chemotherapeutic 
doxorubicin to the cellular cytoplasm. We began with doxorubicin because its inherent 
fluorescence allowed us to visualize its encapsulation within Connectosomes. We note 
that doxorubicin may not be an ideal candidate for delivery via Connectosomes, owing to 
its cardiotoxicity and the importance of connexins in heart tissue. However, any small 
molecule drug or biomolecule can in principle be encapsulated within Connectosomes, 
and nanoparticles in general have not been observed to accumulate in the heart55,56. 
Further, incorporation of targeting ligands has recently been demonstrated to dramatically 
increase binding specificity of cell derived vesicles to target cells overexpressing 
biomarkers such as the epidermal growth factor receptor (EGFR)57. 
To encapsulate doxorubicin within Connectosomes, we treated donor cells with 
doxorubicin (Figure 2.4a), such that the plasma membrane blebs derived from these cells 
contained the drug (Figure 2.4b-c). Notably, chemotherapeutics such as doxorubicin 
require 2-3 days to substantially impact cell viability16, while harvesting Connectosomes 
requires only a few hours (see methods). Therefore, loss of donor cell viability owing to 
drug loading was found to be insignificant during the Connectosome production process. 
Additionally, it is important to note that doxorubicin could be encapsulated within 
Connectosomes either by loading the cells with the semi-membrane permeable drug, or 
by opening and subsequently closing the connexons of preformed Connectosomes in the 
presence of a solution of the drug. Loading of the cells prior to Connectosome extraction 
was found to slightly increase the concentration of encapsulated drug and the overall 
material yield (ie. Connectosomes per donor cell) and was therefore used to produce the 
Connectosomes for the doxorubicin studies presented here. 
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We quantified the doxorubicin content of the Connectosomes by measuring their 
fluorescence emission after resuspending them in fresh solution (Supporting Information 
Figure 2.9). The native fluorescence of empty Connectosomes was measured and 
determined negligible. Based on the peak fluorescence emission of each Connectosome 
sample and a calibration curve of free doxorubicin fluorescence emission, we were able 
to determine that the average concentration of doxorubicin in each Connectosome sample 
was in the micromolar range. Based on this value as well as the average diameter and 
number of Connectosomes per volume, we estimated that the concentration of 
doxorubicin within Connectosomes was approximately 1 mM. Notably, this 
concentration could be further increased by crystalizing doxorubicin within vesicles, as is 
done in the preparation of conventional liposomal formulations4. 
We then investigated the timescale of doxorubicin release from Connectosomes 
(Figure 2.4d). To begin, we measured the fluorescence of doxorubicin-loaded 
Connectosomes using flow cytometry (Figure 2.4e). After addition of EGTA and EDTA 
chelators to remove residual calcium and open connexons, the average doxorubicin 
fluorescence of the Connectosomes decreased significantly within 5 minutes. These 
results demonstrate the potential for rapid drug release upon connexon opening. In 
contrast, when chelators were not added, the vesicles retained their content throughout 
the time course of all experiments.  
Next, we conducted a control study in which the viability of a confluent 
monolayer of HeLa cells was measured 24 hours after free doxorubicin was added 
directly to the cell media at increasing concentrations from 100 nM to 100  µM (Figure 
2.4f-g, i, Supporting Information Figure 2.10). The cytotoxic dose of doxorubicin for 
HeLa cells after 24 hours of exposure is approximately 10 µM58. We evaluated cell 
viability using both trypan blue and 7-AAD cell permeability assays on at least 3 
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independent populations of cells per condition per stain. As expected, we found a trend of 
decreasing cell viability with increasing doxorubicin concentration. Specifically, while a 
dose of 100 nM was not significantly cytotoxic (9% trypan blue / 10% 7-AAD), the 
percentage of nonviable cells increased with increasing doxorubicin dose at 1 µM (21% 
trypan blue / 9% 7-AAD), 10 µM (44% trypan blue / 45% 7-AAD), and 100 µM (87% 
trypan blue) (Figure 2.4g, i). Cells receiving 100 µM doxorubicin were outside the range 
of sensitivity for the 7-AAD assay, therefore, the percentage of nonviable cells at this 
concentration measured using the trypan blue assay was used in Figure 2.4g. 
Then, we conducted a study in which the viability of a confluent monolayer of 
HeLa cells was measured 24 hours after conventional, commercially sourced liposomal 
doxorubicin was added directly to the cell media at increasing doxorubicin concentrations 
from 10 nM to 1  mM (Figure 2.4f-g, i, Supporting Information Figure 2.10). These 
experimental parameters are consistent with the systemic infusions used to administer 
liposomal doxorubicin in the clinical setting. We evaluated cell viability using both 
trypan blue and 7-AAD cell permeability assays on at least 3 independent populations of 
cells per condition per stain. We found that the LD50 of liposomal doxorubicin was more 
than an order of magnitude greater than the LD50 of free doxorubicin (Figure 2.4g,i). 
This result confirms previous reports, and likely arises from the inhibited release of 
doxorubicin when encapsulated within a liposome16. 
Finally, we exposed confluent HeLa cell monolayers to doxorubicin-loaded 
Connectosomes for 2 hours (Figure 2.4f). Independent cell samples were exposed to 
increasing concentrations of Connectosomes, which were equivalent in terms of total 
doxorubicin content to free doxorubicin concentrations of 15 nM, 150 nM, 400 nM, and 
1.5 µM. As discussed above, these concentrations were determined by measuring the 
doxorubicin fluorescence emission for each sample (Supporting Information Figure 2.9). 
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While the 15 nM Connectosome dose was not significantly cytotoxic (7% 7-AAD), the 
percentage of nonviable cells increased with increasing Connectosome concentration at 
150 nM (18% 7-AAD), 400 nM (74% 7-AAD), and 1.5 µM (75% 7-AAD) (Figure 2.4g-
h, Supporting Information Figure 2.11). To confirm our results, we repeated the 
experiment with doxorubicin-loaded Connectosomes at the lowest effective dose, 400 
nM, measuring viability using the trypan blue assay (Figure 2.4i). The results of this 
study were comparable to the results of the 7-AAD assay.
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Figure 2.4:  Continued on next page. 
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Figure 2.4: Connectosomes substantially reduced the cytotoxic dose of doxorubicin. (a-c), Plasma 
membrane blebs were extracted from donor cells treated with doxorubicin to produce doxorubicin-loaded 
Connectosomes. (d), Schematic illustrating doxorubicin release from Connectosomes. (e), Average 
Connectosome fluorescence calculated from flow cytometry data. Connectosomes released significant 
amounts of doxorubicin within 5 minutes of calcium removal. The error bars represent the standard 
deviations of 3 independent trials, at least 800 Connectosomes analyzed per trial. (f),Schematic illustrating 
the 3 modes of drug delivery tested. (g), Percentage of nonviable HeLa cells after free doxorubicin 
treatment (blue), conventional liposomal doxorubicin treatment (purple), or doxorubicin-loaded 
Connectosome treatment (green). All points were measured using a 7-AAD viability assay, except for the 
free doxorubicin 105 nM point, which was measured using a trypan blue viability assay, owing to 
interference of doxorubicin in the 7-AAD measurement at this high doxorubicin concentration. The error 
bars represent the standard deviations of at least 3 independent trials, at least 4,000 cells (7-AAD assay) or 
93 cells (trypan blue) analyzed per trial. (h), Flow cytometry histograms showing 7-AAD fluorescence for 
cells receiving doxorubicin-loaded Connectosomes at increasing equivalent free doxorubicin (dox) 
concentrations. The dotted line represents the threshold fluorescence value above which cells were 
considered nonviable. Each curve represents 3 independent, concatenated trials, at least 4,000 cells 
analyzed per trial. (i), Percentage of nonviable cells determined using both trypan blue (blue) and 7-AAD 
(green) viability assays. The error bars represent the standard deviations of at least 3 independent trials, at 
least 4,000 cells (7-AAD assay) or 93 cells (trypan blue assay) analyzed per trial. (j), Percentage of 
nonviable MCF-7 cells after free doxorubicin treatment (blue) or doxorubicin-loaded Connectosome 
treatment (green). All points were measured using a trypan blue viability assay.  The error bars represent 
the standard deviations of 3 independent trials, at least 166 cells analyzed per trial. Scale bars: 2 µM. 
Asterisks represent statistically significant differences (two-tailed t-test, p < 0.02). Image in (b) 
intentionally saturated to show doxorubicin-loaded Connectosome formation. 
To test Connectosomes in a second model cell line, we repeated our assay using 
recipient MCF-7 cells. MCF-7 cells are human breast adenocarcinoma cells that have 
been used frequently in studies of drug delivery materials59. First, we conducted a control 
study in which the viability of a confluent monolayer of MCF-7 cells was measured 48 
hours after free doxorubicin was added directly to the cell media at increasing 
concentrations from 10 nM to 100  µM (Figure 2.4j). Next, we exposed independent cell 
samples to increasing concentrations of Connectosomes, which were equivalent in terms 
of total doxorubicin content to free doxorubicin concentrations of 180 nM, 900 nM, and 
4.5 µM. While the majority of cells treated with Connectosomes at an equivalent 
doxorubicin concentration of 900 nM were nonviable (61% 7-AAD trypan blue), the 
majority of cells treated with free doxorubicin remained viable even at a concentration of 
100 µM (44% trypan blue), consistent with literature reports60 (Figure 2.4j). 
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As illustrated by these collective results, the therapeutically effective dose (LD50) 
of doxorubicin increases by more than an order of magnitude when the drug is 
encapsulated within a conventional liposome, rather than administered to cells as a free 
drug in solution. This result, which is in agreement with the original literature on 
liposomal doxorubicin in vitro16, points to a key limitation of liposomal formulations that 
has prevented their broad clinical adoption to date. Specifically, their ability to 
concentrate drugs is largely negated by a corresponding reduction in the availability of 
the encapsulated drug to the cellular cytoplasm. In contrast, the LD50 for doxorubicin-
loaded Connectosomes is more than an order of magnitude less than the LD50 for free 
doxorubicin and several orders of magnitude less than the LD50 for liposomal 
doxorubicin. These results illustrate the ability of Connectosomes to dramatically 
increase the efficiency of drug delivery to the cellular cytoplasm, removing a key 
limitation of liposomal formulations4. 
Conclusion 
Here we report the development of Connectosomes, a cell-derived material that 
efficiently delivers molecular cargoes across the plasma membrane barrier. By utilizing 
gap junction channels, Connectosomes make it possible to sequester reagents and drugs 
in a particle, yet release them rapidly and efficiently into the cellular cytoplasm. By 
combining these two capabilities, Connectosomes represent a key step toward realizing 
the long-anticipated advantages of particle-based drug delivery materials. In particular, 
this bio-inspired delivery approach has led to a remarkable decrease in the therapeutically 
effective dose of doxorubicin, which has the potential to address long-standing problems 
associated with chemotherapy, such as dose-limiting toxicity. Further, this result implies 
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the ability to rapidly increase the drug concentration within the cytoplasm, suggesting the 
potential to outpace cellular efflux pumps, a key mechanism of multidrug resistance. 
The focus of this work has been on fundamental development of Connectosomes 
as liposomal materials that utilize gap junctions to create a new molecular delivery route 
to the cytoplasm. However, in the future, these materials could create a path forward for 
efficient intracellular delivery of hydrophilic drugs and small biologics, including 
peptides, siRNA, and other compounds with intracellular targets31. As evidence of this 
potential, in Figure 2.2c, a hydrophilic dye, Atto 594, passed through the connexon 
channels of Connectosomes. In drug design, lack of membrane permeability is currently 
considered a severe disadvantage that immediately eliminates compounds from drug 
candidate libraries. However, gap junction-based delivery could remove this requirement, 
substantially expanding the chemical diversity of drug candidates to include those with 
high polarity and significant negative charge1. For example, this approach could improve 
the cytoplasmic delivery of drugs that have not been successful in liposomal formulations 
because they lack membrane permeability, such as cisplatin3. Ultimately, by dramatically 
improving molecular transport across the plasma membrane barrier, Connectosomes have 
the potential to improve the performance of existing drugs and enable the design of new 
therapeutics and biochemical reagents that reach a broader class of cytoplasmic targets. 
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Supporting Information 
Figure 2.5: Exogenously-loaded Connectosomes encapsulated a membrane impermeable dye. (a), 
Connectosomes excluded CRO dye in a solution of 2 mM Ca2+ (top), but filled with dye when Ca2+ was 
removed (bottom). (b), Percentage of Connectosomes including dye +/- Ca2+. The error bars represent the 
standard deviations of 3 independent trials; at least 39 Connectosomes analyzed per trial. Scale bars: 2 µm. 
Asterisk represents statistically significant differences (two-tailed t-test, p < 0.002).
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Figure 2.6: Connectosomes (arrows) delivered dye to the cytoplasm. Brightfield and confocal 
fluorescence images. Scale bars: 20 µm. Connectosomes intentionally saturated to show intracellular dye 
accumulation. 
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Figure 2.7: Connectosomes delivered CRO dye to the cytoplasm. (a-d), Side-scatter versus forward-
scatter plots showing all events detected in 3 independent, concatenated trials for untreated cells (a) and 
cells treated with carbenoxolone (b), carbenoxolone + CRO dye-loaded Connectosomes (d), and CRO dye-
loaded Connectosomes (d). The gate shown was used for analysis in Fig. 3. (e), Average recipient cell 
fluorescence for the ungated samples for each condition. These results show approximately the same trend 
and relative magnitudes as the data in Fig. 3, demonstrating that the result of the experiment does not 
depend on the choice of the gate. For each trial, at least 17,000 events were detected. At least 10,000 of 
these events fell within the gate and were analyzed in Fig. 3. The error bars represent standard deviations of 
3 independent trials. M stands for million. 
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Figure 2.8: Dye delivery is dependent on gap junction assembly. (a), Flow cytometry histograms 
showing CRO dye fluorescence for each recipient cell condition: (i) untreated cells, (ii) cells treated with 
CRO-loaded blebs from A549 cells lacking connexin expression, (iii) Connectosomes derived from HeLa 
cells stably expressing Cx43. Each curve represents 3 independent, concatenated trials, at least 10,000 cells 
analyzed per trial. The population of highly fluorescent cells (centered around 106), which is only present 
for cells exposed to Connectosomes, represents the fraction of cells that received a substantial dose of CRO 
dye. In contrast, cells treated with CRO-loaded blebs derived from A549 cells do not have significantly 
greater fluorescence than untreated cells. (b), Average recipient cell fluorescence for each condition, 
normalized to the average recipient cell fluorescence for cells treated with Connectosomes. The error bars 
represent the standard deviations of 3 independent trials, at least 10,000 cells analyzed per trial. Legend in 
(a) applies to (b). Asterisk represents statistically significant differences (two-tailed t-test, p < 0.003). 
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Figure 2.9: Connectosomes contained doxorubicin. (a), A representative fluorescence spectrum of 
doxorubicin-loaded Connectosomes (blue), compared to empty Connectosomes (green). Connectosomes 
were washed to remove free doxorubicin from solution. (b), A calibration curve of doxorubicin 
fluorescence in solution (green) was generated by plotting the peak of the fluorescence spectrum for each 
concentration of doxorubicin dissolved in aqueous solution. A line was fit to this curve and the doxorubicin 
content of the Connectosomes (blue) was estimated by calculating the doxorubicin concentration 
corresponding to the measured fluorescence. The error bars represent the standard deviations of 3 
independent trials. 
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Figure 2.10:  Continued on next page 
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Figure 2.10: Thresholds for 7-AAD viability assay. (a-o), Flow cytometry histograms showing 7-AAD 
fluorescence histograms for cells with and without 7-AAD for each condition. Legend in (a) applies to (b-
o). The dotted line represents the threshold fluorescence value above which cells were considered 
nonviable, for untreated cells (a), and for cells treated with 100 nM (b), 1µM (c), and 10 µM (d) free 
doxorubicin, for cells treated with empty Connectosomes (e) and doxorubicin-loaded Connectosomes at 
equivalent doxorubicin concentrations of 15 nM (f), 150 nM (g), 400 nM (h), and 1.5 µM (i), and for cells 
treated with liposomal doxorubicin at equivalent doxorubicin concentrations of 10 nM (j), 100 nM (k), 1 
µM (l), 10 µM (m), 100 µM (n), and 1 mM (o). Each curve represents 3 independent, concatenated trials, at 
least 4,000 cells analyzed per trial.
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Figure 2.11: Doxorubicin-loaded Connectosomes were cytotoxic to HeLa cells. Brightfield images. 
(a), Untreated, control HeLa cells. (b), Cells after treatment with doxorubicin-loaded Connectosomes at an 
equivalent doxorubicin dose of 400 nM. Scale bars: 200 µm. 
                
 51 
Materials and Methods 
Chemical reagents. CellTrace Calcein Red-Orange AM and trypan blue were 
purchased from Life Technologies. Sodium phosphate, DTT (dithiothreitol), PFA 
(paraformaldehyde), doxycycline, glycine, Atto 594-NHS ester, imidazole, NaCl, CaCl2, 
EGTA (ethylene glycol tetraacetic acid), EDTA (ethylenediaminetetraacetic acid), 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), DMSO (dimethyl 
sulfoxide) and doxorubicin were purchased from Sigma-Aldrich. Fetal bovine serum 
(FBS), trypsin, penicillin, streptomycin, L-glutamine, PBS (phosphate buffered saline), 
and DMEM (Dulbecco’s modified Eagle medium) were purchased from GE Healthcare. 
Puromyocin was purchased from Clontech. Geneticin (G418) was purchased from 
Corning. Leupeptin and pepstatin were purchased from Roche. PMSF 
(phenylmethanesulfonyl fluoride), β-ME (β-mercaptoethanol) were purchased from 
Fisher Scientific. 7-AAD (7-amino-actinomycin D) was purchased from Affymetrix 
eBioscience. Conventional liposomal doxorubicin (Dox-NP) was purchased from Avanti 
Polar Lipids. All chemical reagents were used without further purification. 
Cell culture. Stably transfected, inducible tet-on cells expressing connexin 43 
with a C terminal YFP modification were a gift from Matthias Falk52,53. These cells were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal 
Bovine Serum (FBS), 1% penicillin, 1% streptomycin, 1% L-glutamine (PSLG), 100 
µg/ml geneticin and 0.4 µg/ml puromycin. To induce Cx43YFP expression, cells were 
incubated with 1 µg/mL doxycycline. Wild type HeLa, MCF-7, and MD-MB-231 cells 
were cultured in DMEM supplemented with 10% FBS and 1% PSLG. Cell media was 
changed every 48-72 hours. Cells were incubated at 37 °C with 5% CO2. All studies were 
conducted on the fifth day after plating. 
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Optical microscopy. Fluorescence and brightfield images have been optimized for 
contrast and brightness. A Zeiss AxioObserver microscope with 10x and 20x objectives 
was used for widefield imaging. A Zeiss AxioObserver Spinning Disk Confocal 
microscope with 100x oil immersion (numerical aperture, 1.4) and 63x oil immersion 
(numerical aperture, 1.4) objectives was used for both fluorescence and brightfield 
imaging. Three filters were used:  an emission filter centered at 525 nm with a 50nm 
width, an emission filter centered at 629 nm with a 62 nm width, and a triple pass 
dichroic mirror designed to reflect laser illumination at 405 nm, 488nm, and 561 nm 
excitation wavelengths. For spinning disk confocal and brightfield imaging, cells were 
cultured on 35 mm collagen-coated glass bottom dishes (MatTek). 
Flow cytometry. A BD Accuri C6 Flow Cytometer was used for all flow 
cytometry studies and all flow cytometry data was analyzed using FlowJo software. Flow 
cytometry data was collected at a speed of 35 events per second. Gates were drawn to 
include at least 30% of the detected events. In each experiment, once the appropriate gate 
was determined it was applied to all trials and all experimental conditions without 
modification. 
Connectosome formation. Following established protocols for making giant 
plasma membrane vesicles (GPMVs)54, Connectosomes were formed by rinsing donor 
connexin 43-YFP HeLa cells twice with GPMV buffer (10 mM HEPES, pH 7.4, 2 mM 
CaCl2, 150 mM NaCl) and once with active buffer (10 mM HEPES, pH 7.4, 2 mM CaCl2, 
150 mM NaCl, 25 mM PFA, 2 mM DTT, 125 mM glycine). Then, the cells were 
incubated for 6 hours in active buffer, and the active buffer containing the 
Connectosomes was collected from the cells. To concentrate the Connectosomes, the 
sample was centrifuged at 17,000 x g for 20-30 minutes at 4 °C. Finally, the 
Connectosome pellet was resuspended in fresh GPMV buffer. To determine the average 
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Connectosome diameter, the diameters of 154 Connectosomes were measured from 
brightfield images. To determine the average percentage of Connectosomes containing 
connexin 43-YFP embedded in the membrane, confocal spinning disk and brightfield 
images of 3 independent samples of Connectosomes were analyzed for fluorescence in 
the membrane. At least 37 Connectosomes were analyzed per trial. 
MDA-MB-231 plasma membrane bleb formation.  MDA-MB-231 plasma 
membrane blebs were formed from MDA-MB-231 donor cells as described above. 
YFP purification. The pET28a-HisYFP-Sp100 plasmid was generously shared by 
the lab of Frauke Melchior (Addgene plasmid #53141)55. Following the provider’s 
protocol55, hisYFP-Sp100 was expressed in BL21(DE3)pLysS cells for 1 hour at 18 °C 
and then 5 hours at 30 °C. 
Bacterial extracts were made by lysing the cells in 50 mM Na3PO4, pH 8.0, 300 
mM NaCl, 20 mM imidazole, 1 mM β-ME, and 1 µg/mL each of leupeptin, pepstatin, 
and PMSF. HisYFP-Sp100 was purified by incubating with Ni-NTA agarose beads. After 
washing with 50 mM Na3PO4, pH 8.0, 300 mM NaCl, 20 mM imidazole, 1 mM β-ME, 
and 1 µg/mL each of leupeptin, pepstatin, and PMSF, proteins were eluted in 250 mM 
imidazole. Eluted proteins were concentrated and dialyzed in 50 mM Na3PO4, pH 8.0, 
300mM NaCl, 1 mM β-ME at 4 °C overnight followed by a second 2 hour dialysis at 4 
°C. The final protein concentration was calculated from the absorbance spectrum 
measured on a Nanodrop 2000 spectrophotometer (Thermo Scientific).  
Quantification of connexon density on Connectosome surfaces. Purified SP100-
YFP was serially diluted to generate a calibration curve of protein concentration. The 
YFP fluorescence of the calibration curve and a sample of 8.9 x 106 Connectosomes were 
measured in a BioTek Cytation 3 fluorimeter to calculate the average molar concentration 
of YFP molecules in the Connectosome sample. The molar concentration was converted 
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to number of YFP molecules and divided by the number of Connectosomes per sample to 
achieve an average number of connexin 43-YFP molecules per Connectosome. Finally, 
the surface area per Connectosome was calculated from the average diameter described 
above to determine a density of connexons per Connectosome. The percentage of the 
Connectosome surface covered by connexons was estimated using the approximate 
membrane area per connexon channel in cellular connexin plaques38, 70 nm2.  
Calcein red-orange loading. A stock solution of calcein red-orange (CRO) 
acetomethoxy (AM) dye in DMSO was prepared at a concentration of 1.7 mg/mL and 
diluted to a final concentration of 17 ng/µL in GPMV buffer. To form CRO dye-loaded 
Connectosomes or MD-MB-231 plasma membrane blebs, donor cells were incubated in 
the CRO AM dye solution for 30 minutes immediately before extraction of membrane 
blebs. 
Connexon function study. For the CRO dye release study, Connectosomes 
containing CRO dye were formed from donor cells as described above. Connexon 
channels were opened by removing calcium from the solution by adding EGTA and 
EDTA to a final concentration of 5 mM at pH greater than 8.5. Three independent 
samples of Connectosomes were imaged within 2 hours of EGTA and EDTA addition, 
and examined for luminal fluorescence above the background level. At least 54 
Connectosomes were analyzed for each trial. 
To demonstrate the connexon-dependence of the dye release, MDA-MB-231 
plasma membrane blebs containing CRO dye were formed from MDA-MB-231 donor 
cells as described above. Connexon channels were opened by removing calcium from the 
solution by adding EGTA and EDTA to a final concentration of 5 mM. Three 
independent samples of MDA-MB-231 plasma membrane blebs were imaged within 2 
hours of EGTA and EDTA addition, and examined for luminal fluorescence above the 
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background level. At least 36 MDA-MB-231 plasma membrane blebs were analyzed for 
each trial. 
For the Atto 594 and Atto 488 studies, a 10 µM stock solution of Atto 594-NHS 
Ester (with NHS ester hydrolyzed) or Atto 488-NHS Ester (with NHS ester hydrolyzed) 
was prepared in GPMV buffer. Atto 594 was added to preformed Connectosomes in 
GPMV buffer at a final concentration of 20 nM, and Atto 488 was added to preformed 
Connectosomes at a final concentration of 200 nM. To remove calcium from solution, 
EGTA and EDTA were added to the Connectosomes as described above. Three 
independent samples of Connectosomes were imaged within 1 hour of EGTA and EDTA 
addition, and examined for luminal fluorescence above the background level. At least 51 
Connectosomes were analyzed for each trial for the Atto 594 study, and at least 39 
Connectosomes were analyzed for each trial for the Atto 488 study. 
For the photobleaching study, Atto 594 dye within Connectosomes was bleached 
using a 561 nm laser on the spinning disk confocal microscope described above. Then, 
laser illumination was stopped and images were taken every 15 seconds for 75 seconds.  
Dye delivery study. Recipient HeLa cells were plated in a 12 well plate at a 
density of 25,000 cells per well and a total media volume of 2 mL per well. Seven hours 
before addition of the Connectosomes, the recipient cells received fresh media. The 
media for the blocked condition was supplemented with 300 µM carbenoxolone, 
prepared from a 100 mM stock in water. Just before addition of the Connectosomes, the 
recipient cells were rinsed once with 2 mL PBS and then incubated in 500 µL fresh PBS. 
Recipient cells for the blocked condition were incubated in PBS supplemented with 300 
µM carbenoxolone. For each trial, an independent sample of CRO dye-loaded 
Connectosomes was formed using GPMV buffer without calcium. Concentrated 
Connectosomes were resuspended in fresh GPMV buffer without calcium and counted 
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with a hemocytometer. Connectosomes were added to recipient cells at a ratio of 
approximately 1 Connectosome per 2 recipient cells and incubated in the dark at 37 °C 
and 5% CO2 for 2 hours. This ratio was estimated based on hemocytometer counts of the 
number of collected Connectosomes and of the number of recipient cells in a single well 
of a 12 well plate. After incubation, the recipient cells were rinsed with 2 mL PBS to 
remove the Connectosomes and then imaged or prepared for flow cytometry. For flow 
cytometry, the recipient cells were trypsinized with 500 µL trypsin for 5 minutes at 37 
°C, 5% CO2 and then quenched with 1500 µL media and centrifuged for 5 minutes at 300 
x g. The cell pellet was resuspended in 100 µL PBS before flow cytometry. At least 
10,000 cells were analyzed for each trial. In a separate experiment, CRO dye-loaded 
plasma membrane vesicles derived from A549 cells were incubated with recipient HeLa 
cells plated in a 96 well plate at 6,000 cells per well for one hour before being analyzed 
using flow cytometry as described above. An equivalent number of CRO dye-loaded 
Connectosomes were incubated with a separate population of recipient HeLa cells. 
Doxorubicin loading. A 10 mM stock solution of doxorubicin was prepared in 
DMSO. To form doxorubicin-loaded Connectosomes, donor cells were incubated in a 1 
mM doxorubicin solution in active buffer without calcium for 30 minutes immediately 
before Connectosome formation. After 30 minutes, the doxorubicin was diluted to a final 
concentration of 200 µM in active buffer without calcium and remained throughout the 
duration of blebbing. After formation, doxorubicin-loaded Connectosomes were collected 
as described above and then washed with 1 mL fresh GPMV buffer without calcium. 
Connectosomes were then resuspended in fresh GPMV buffer without calcium. 
Doxorubicin encapsulation measurement. To estimate the amount of 
doxorubicin encapsulated within the Connectosomes, free doxorubicin was serially 
diluted to generate a calibration concentration curve (n=3). The doxorubicin fluorescence 
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of the calibration curve, 3 independent samples of 3 x 105 doxorubicin-loaded 
Connectosomes, and 3 independent samples of 3 x 105 empty Connectosomes was 
measured in a BioTek Cytation 3 fluorimeter to determine the average molar doxorubicin 
concentration of the Connectosome samples. This molar concentration was converted to 
moles of doxorubicin and divided by the approximate total volume of all Connectosomes 
(based on the number of Connectosomes in the sample and the average diameter of 
Connectosomes) present in the sample to estimate the concentration of doxorubicin inside 
the Connectosomes. 
Doxorubicin release study. Doxorubicin-loaded Connectosomes were formed as 
described above. The initial doxorubicin content of the Connectosomes was measured 
using flow cytometry. EGTA and EDTA were added to the Connectosome solution as 
described above in the connexon function studies in order to open the connexon channels. 
Using flow cytometry, the final doxorubicin content of the Connectosomes was then 
measured 5 minutes after EGTA and EDTA addition. Three independent Connectosome 
samples were analyzed for each condition, and at least 800 Connectosomes were 
analyzed for each trial. 
Doxorubicin cytotoxicity study. Recipient HeLa cells were plated in a 12 well 
plate at a density of 25,000 cells per well and a total media volume of 2 mL media per 
well. Recipient MCF-7 cells were plated in a 48 well plate at a density of 100,000 cells 
per well and a total media volume of 2mL media per well. Seven hours before addition of 
the Connectosomes, recipient cells received fresh media. Just before addition of the 
Connectosomes, the recipient HeLa cells were rinsed once with 2 mL PBS and then 
incubated in 500 µL fresh PBS, while the recipient MCF-7 cells were rinsed once with 
2mL media and then incubated in 500 µL fresh media. For each trial, a sample of 
doxorubicin-loaded Connectosomes was formed as described above. Concentrated 
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Connectosomes were resuspended in fresh GPMV buffer without calcium and counted 
using a hemocytometer. The doxorubicin encapsulated within each sample of 
Connectosomes was determined as described above. Connectosomes were added to 
recipient cells at increasing equivalent doxorubicin doses and incubated in the dark at 37 
°C with 5% CO2 for 2 hours (recipient HeLa cells) or 48 hours (recipient MCF-7 cells). 
After incubation, the recipient cells were rinsed with 2 mL media and then incubated in 2 
mL fresh media at 37 °C with 5% CO2. After 24 hours, HeLa cell viability was analyzed 
using a trypan blue or 7-AAD assay. MCF-7 cell viability was analyzed directly after 
Connectosome incubation using a trypan blue assay. 
For the trypan blue assay, the cells were detached with 500 µL trypsin for 5 
minutes at 37 °C, 5% CO2. Trypsinized cells were then quenched with 1.5 mL media and 
pelleted for 5 minutes at 300 x g. The cell pellet was resuspended in 200 µL media, and 
trypan blue was added to the cells at a volume ratio of 1:1. At least 93 cells were counted 
for each trial using a hemocytometer. Cells including the trypan blue stain were 
considered non-viable and cells excluding the trypan blue were considered viable.  
For the 7-AAD assay, the cells were trypsinized with 500 µL trypsin for 5 
minutes at 37 °C, 5% CO2. Trypsinized cells were then quenched with 1.5 mL media and 
centrifuged for 5 minutes at 300 x g. The cell pellet was resuspended in 100 µL PBS. 
Five µL of 7-AAD was added to 45 µL of the resuspended cells, and analyzed using flow 
cytometry three minutes after 7-AAD addition. At least 5,000 cells were analyzed for 
each trial. To determine the percentage of non-viable cells in each sample, a threshold 
was drawn on the flow cytometry fluorescence histograms at the minimum point between 
the population of cells excluding the dye and the population of cells including the dye 
(See fig. S4). The percentage of cells with fluorescence above these thresholds were 
considered non-viable. 
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The relationship between the concentration of doxorubicin added via solution and 
cell viability was determined by incubating recipient HeLa cells in the specified 
doxorubicin concentration diluted in media from a 10 mM stock in DMSO for 24 hours. 
Cell viability was measured using both viability assays as described above. 
The relationship between the concentration of doxorubicin added via conventional 
liposomal doxorubicin (Dox-NPs) and cell viability was determined by incubating 
recipient HeLa cells in the specified doxorubicin concentration diluted in media for 24 
hours. Cell viability was measured using both viability assays as described above. The 
concentration of doxorubicin within DOX-NPs was provided by the manufacturer. 
Statistical analysis. As noted throughout the main text and methods sections, at 
least three independent trials are reported for all experimental results. In each case where 
a statistically significant comparison is reported based on this data (Figs. 2B, 2G, 3D-E, 
4E), an unpaired, two-tailed student’s t-test, with unequal sample variance, was 
performed and yielded a probability value no greater than 5%. 
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Chapter 3:  Connectosomes for Direct and Specific Molecular Delivery 
to the Cellular Cytoplasm 
Abstract 
Gap junctions are a promising new frontier for therapeutic delivery. 
Connectosomes, an emerging technology, are cell-derived vesicles that are capable of 
forming gap junctions with cells and delivering their encapsulated cargo directly to the 
cytoplasm. Remarkably, by using gap junctions to create a direct route for molecular 
transport that bypasses the plasma membrane barrier, these materials dramatically 
increase the effectiveness of chemotherapeutic drugs. However, nonspecific interactions 
of these particles with healthy tissues is a major obstacle that limits their potential as 
relevant therapeutic vehicles. To achieve directed cytoplasmic delivery, we have 
developed targeted Connectosomes. Specifically, by embedding multi-functional, multi-
domain targeting proteins into the membrane surfaces of Connectosomes, we 
demonstrate their ability to selectively interact with target cells on the basis of cell-
surface receptor expression. Here we show that targeting enhances Connectosome 
binding to target cells, and selectively increases the efficiency of cytoplasmic transport. 
Further, using targeted Connectosomes to deliver the chemotherapeutic drug doxorubicin 
reduces the therapeutically effective dose of the drug by a factor of two for target cells. 
More generally, our approach has the potential to boost cytoplasmic delivery of diverse 
therapeutic molecules to specific cell populations while protecting off-target cells, a 
critical step toward realizing the therapeutic potential of gap junctions. 
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Introduction 
Gap junctions, transmembrane channels that connect the cytoplasm of adjacent 
cells, are emerging as a promising new route for therapeutic drug delivery1-4. Formed 
from hexameric connexin proteins, gap junctions are traditionally considered to be 
facilitators for exchange of metabolites, ions, second messengers and other signaling 
molecules between cells5. However, gap junctions also enable drug transfer between cells 
through the bystander effect6, in which therapeutics permeate tissues by using gap 
junctions to pass from the cytoplasm of one cell to its neighbors. Through this intriguing 
phenomenon, gap junctions enhance the efficacy of numerous therapeutics, including 
paclitaxel7, doxorubicin7, gemcitabine8, etoposide7, and others9, demonstrating the 
potential importance of gap junctions as therapeutic conveyers. Further, it has recently 
been proposed that the presence of gap junction channels in exosomes underlies their 
ability to deliver siRNA, further suggesting their therapeutic potential2. 
Inspired by the natural ability of cells to transfer chemotherapeutics between gap 
junctions, we recently developed Connectosomes, cell-derived lipid vesicles that contain 
functional, embedded gap junction channels1. Capable of forming complete gap junctions 
with cells, Connectosomes increase the efficacy of doxorubicin delivery by several orders 
of magnitude compared to traditional liposomal formulations of doxorubicin, illustrating 
the therapeutic importance of direct access to the cell cytoplasm. By creating a new 
avenue for molecular transport that bypasses the plasma membrane barrier, 
Connectosomes and other gap junction vesicles4 create a path forward for efficient 
cytoplasmic delivery of diverse molecules, such as existing therapeutics as well as 
membrane-impermeable drugs and reagents. However, since connexin proteins are found 
ubiquitously in cells throughout the tissue of the body10, nonspecific drug interactions 
with healthy tissues could limit the translational relevance of these vesicles. Therefore, 
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development of a chemotherapeutic delivery system that can both efficiently and 
selectively kill diseased cells while protecting healthy, off-target tissue is an important 
step in the realization of gap junction-based therapeutic delivery approaches. 
To precisely target tumor cells, biochemical moieties that recognize tumor-
specific cell surface receptors can be incorporated onto the surfaces of therapeutic 
delivery particles11. By promoting preferential interaction of the particles with tumor cells 
that overexpress specific receptors, these targeting ligands improve the specificity of drug 
delivery. The advantages of targeting have been well-documented for synthetic 
nanoparticles, as ligands including antibodies12-14, organic compounds15, 16, and peptides17 
have been used to direct therapeutics to a diverse range of specific cell populations18. 
These approaches have also been extended to cell-derived materials. For example, folic 
acid has been conjugated to virus-like particles for doxorubicin delivery to ovarian cancer 
cells19, anti-CD43 antibodies have been conjugated to red blood cells to target CD43 
positive leukocytes20, and iron oxide nanoparticles have been conjugated to cell-derived 
microvesicles to deliver doxorubicin to target tissues via an external magnetic field21. 
However, chemical conjugation of targeting moieties to nanoparticles inherently 
limits the complexity of these approaches. More recently, several groups have harnessed 
the cell’s own machinery to incorporate targeting peptides into cell-derived vesicles22.  
For example, RVG peptide has been used to target exosomes to acetylcholine receptors in 
the brain for siRNA delivery23, GE11 peptide has been used to target exosomes to EGFR 
receptors in breast cancer cells for miRNA delivery24, iRGD peptide has been used to 
target exosomes to integrin breast cancer cells for doxorubicin delivery25, and CCR5 has 
been used to target cell-derived liposomes to HIV-infected cells for EDTA delivery26. 
Inspired by this work but desiring a more tunable system, capable of fully harnessing the 
cell’s ability to manufacture complex, sophisticated macromolecules, our group recently 
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engineered a set of multi-functional, multi-domain transmembrane targeting ligands, 
which selectively increase vesicle binding by a ratio of 50:127. 
Towards designing a targeted drug delivery system which can deliver therapeutic 
molecules directly into the cytoplasm of a specific population of target cells, here we 
have incorporated previously designed multi-functional, multi-domain transmembrane 
targeting proteins27 into Connectosomes. Specifically, we have engineered a mammalian 
cell line which co-expresses connexin 43-YFP and a targeting protein, comprised of a 
transmembrane anchor domain and a multi-functional extracellular domain. Here, the 
multi-functional extracellular domain includes a fluorophore domain for visualization, an 
intrinsically disordered linker domain to prevent steric inhibition, and an affinity domain 
comprised of a single domain camelid antibody against enhanced green fluorescent 
protein (eGFP). Our results show that targeting selectively enhances Connectosome 
binding to target cells by thirty times compared to off-target cells. Additionally, targeting 
selectively increases the efficiency of dye transport to the cytoplasm of target cells by 
five times. Further, using targeted Connectosomes to deliver doxorubicin reduces the 
therapeutically effective dose (LD50) by a factor of 2 for target cells, compared to off-
target cells. Taken together, these data illustrate the potential of targeted Connectosomes 
to serve as efficient vehicles for targeted molecular delivery of chemotherapeutics and 
other diverse drugs to the cell cytoplasm. 
Results and Discussion 
Targeted Connectosome development 
To achieve targeted cytoplasmic delivery, we began by incorporating a chimeric 
targeting protein into the surfaces of the Connectosomes. To demonstrate this general 
targeting strategy, we utilized a previously developed multifunctional targeting protein 
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engineered to selectively bind to any plasma membrane receptor with an eGFP 
modification in its extracellular domain27. Notably, the targeting protein could be 
restructured to selectively bind to other, disease-relevant receptors, such as the epidermal 
growth factor receptor (EGFR), which is a popular target for therapeutic delivery 
systems28. However, in this study, we targeted eGFP-tagged receptors in order to isolate 
the absolute binding specificity of the targeted Connectosomes, as cells do not 
endogenously express these fluorescently-tagged receptors. 
Our targeting protein was comprised of five domains: the intracellular and 
transmembrane domains of transferrin receptor, an mRFP fluorophore domain, an 
intrinsically disordered linker domain comprised of the first 289 amino acids of AP180, 
and an affinity domain. Here, the affinity domain consisted of a single domain camelid 
antibody against eGFP, a nanobody targeting ligand that specifically recognizes eGFP 
and can therefore be used to precisely target cells on the basis of their expression of 
eGFP-tagged plasma membrane receptors27, 29. 
To produce targeted Connectosomes, we co-expressed the eGFP nanobody 
targeting protein (GFPnb-mRFP) in donor HeLa cells that also expressed a fluorescently 
tagged connexin protein (Cx43-YFP) (Figure 3.1a-d). By inducing these donor HeLa 
cells to bleb using established protocols1, 27, 30, we extracted targeted Connectosomes, 
plasma membrane vesicles that contained both connexin and targeting proteins embedded 
in their surfaces (Figure 3.1a-d). Plasma membrane blebbing occurs when the 
cytoskeleton’s attachments to the plasma membrane are disrupted, which can occur 
naturally during cellular processes such as cell motility or cytokinesis31, or as a result of 
chemical induction30. Transmembrane proteins embedded in the plasma membrane 
vesicles that form during blebbing maintain their function and orientation in the 
membrane32, and ours and other groups have recently harnessed this ability in order to 
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develop therapeutic materials that depend on the functionality of embedded 
transmembrane proteins1, 27, 33. Exosomes are similar cell-derived materials with emerging 
therapeutic potential34. However, because protein trafficking to the plasma membrane is 
well understood compared to our understanding of how proteins arrive in exosomal 
membranes35, controlled incorporation of transmembrane proteins into plasma membrane 
vesicles through blebbing is relatively simpler. Therefore, blebbing was used to produce 
targeted Connectosomes for these studies.
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Figure 3.1: Targeted Connectosomes were harvested from donor cells. Confocal fluorescence 
images. (a), Schematic of the targeted Connectosome formation process. (b-d), Giant plasma membrane 
vesicles were harvested from donor cells co-expressing connexin 43-YFP (green) and an RFP-tagged GFP 
nanobody targeting protein (red) to produce targeted Connectosomes. Scale bar in (b) and (c), 10 µm. Scale 
bar in (d), 2 µm. Images intentionally saturated to show membrane expression of the connexin and 
targeting proteins. 
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To test the accessibility and functionality of the eGFP nanobody embedded in the 
targeted Connectosomes, we first exposed HeLa cells expressing the targeting protein to 
soluble eGFP. To enable detection of eGFP binding to the cells, it was necessary here to 
use cells without fluorescent connexin proteins, as the fluorescent signatures of YFP and 
eGFP are difficult to distinguish. Fluorescence imaging revealed that soluble eGFP bound 
significantly to cells expressing the eGFP nanobody, but did not bind to cells lacking 
expression of the targeting protein (Figure 3.2a-b). Then, to investigate whether the 
targeting protein retained its ability to bind eGFP throughout the blebbing process, we 
exposed cells in the process of blebbing to soluble eGFP. Blebbing cells also recruited 
the fluorophore, as did vesicles incubated with soluble eGFP, demonstrating that the 
targeting protein retained its accessibility and functionality throughout the process of 
vesicle formation (Figure 3.2a). Further, fluorescence intensity comparisons of the eGFP 
and mRFP fluorophores revealed that the amount of eGFP bound to each vesicle 
increased with the amount of targeting protein present on the vesicle surface, similarly to 
previous studies on vesicles containing the same targeting protein but derived from a 
different cell line27 (Figure 3.2c). Taken together, these data demonstrate that the targeted 
Connectosomes contain accessible, functional targeting proteins capable of binding to 
eGFP. 
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Figure 3.2: Soluble eGFP recruitment depends on targeting protein expression. (a), Soluble eGFP 
(green) is recruited to cells expressing the targeting protein at each stage of the Connectosome formation 
process. Scale bars in left and middle column 10 µm, right column 5 µm. (b) Soluble eGFP is not recruited 
to cells lacking significant targeting protein expression at the plasma membrane. Scale bar 10 µm. (c), 
Binding of soluble eGFP is positvely correlated with targeting protein expression. 45 vesicles analyzed in 
two membrane regions, each represented by a single point on the plot. Images intentionally saturated to 
show membrane expression of the targeting proteins. 
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Targeting selectively enhanced Connectosome binding to target cells 
Having demonstrated the functionality of the targeting ligands, we next examined 
the ability of the targeted Connectosomes to bind target cells. Unprocessed 
Connectosomes have an average diameter of approximately 10 µm1, but to minimize 
gravitational settling27 and increase therapeutic relevance, targeted Connectosomes were 
extruded using a 1 µm filter for this study. To measure the baseline level of nonspecific 
interactions of the targeted Connectosomes with off-target cells, extruded, targeted 
Connectosomes were incubated with confluent monolayers of recipient HeLa cells, as 
these cells lack eGFP expression. Using established flow cytometry protocols27, binding 
was quantified by measuring the increase in mRFP fluorescence of the recipient cells four 
hours after addition of the vesicles (Figure 3.3a, left). Addition of the targeted 
Connectosomes increased the average mRFP fluorescence of the recipient off-target cells 
by less than 3000 (a.u.) (Figure 3.3b-c). Then, to investigate the ability of targeted 
Connectosomes to bind to target cells, extruded, targeted Connectosomes were incubated 
with confluent monolayers of HeLa cells expressing a chimeric transmembrane eGFP 
receptor protein (eGFPr). The eGFP receptor was comprised of the intracellular and 
transmembrane domains of the transferrin receptor, and an eGFP ectodomain. Addition 
of the targeted Connectosomes increased the average mRFP fluorescence of the recipient 
target cells by nearly 32,000 (a.u.) (Figure 3.3a, bottom; b-c). This ten-fold increase in 
the shift in average mRFP fluorescence upon vesicle addition demonstrates that the 
incorporation of the targeting protein in the Connectosomes enhances target cell binding 
substantially. Fluorescence imaging of these cells further confirmed that targeted 
Connectosomes bound extensively to the surfaces of target cells, and bound minimally to 
off-target cells (Figure 3.3d-e). Taken together, these data suggest that targeting 
selectively enhances Connectosome binding to target cells.
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Figure 3.3: Targeting enhanced Connectosome binding to target cells. (a) Flow cytometry 
histograms showing mRFP fluorescence for recipient off-target (left) and target (right) cells before (blue) 
and after (purple) incubation with extruded, targeted Connectosomes. Each curve represents 3 independent, 
concatenated trials, 5,000 cells analyzed per trial. (b), Average recipient cell mRFP fluorescence for each 
condition. The error bars represent the standard deviations of 3 independent trials, 5,000 cells analyzed per 
trial. (c), Average increase in mRFP fluorescence after incubation with targeted Connectosomes for off-
target and target cells represents the extent to which binding occurred. The error bars represent the standard 
deviations of 3 independent trials, 5,000 cells analyzed per trial. (d), Confocal fluorescence image showing 
targeted Connectosomes bound to target cells. (e), Confocal fluorescence image showing that off-target 
cells recruit targeted Connectosomes much less significantly. All scale bars 10 µm. Legend in (a) applies to 
(b) and (c). 
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To further demonstrate the dependence of targeted Connectosome binding on 
eGFP receptor expression, we then analyzed the relationship between binding and the 
eGFP receptor expression level of the target cells. Specifically, using the eGFP 
fluorescence of the untreated target cells as an indicator for eGFP receptor expression 
level, target cells were equally distributed between five cell groups with increasing eGFP 
receptor expression, such that each group contained 20% of the total cell population 
(Figure 3.4a). The average eGFP fluorescence for these groups increased from 150,000 
(a.u.) for the group with the lowest eGFP receptor expression, to 2,750,000 (a.u.) for the 
group with the highest eGFP receptor expression (Figure 3.4b). For each cell group, 
binding was quantified by measuring the increase in average mRFP fluorescence after 
incubation with targeted Connectosomes (Figure 3.4c-e). As expected, we found that 
Connectosome binding increased with increasing eGFP receptor expression. For 
example, the group of target cells with the lowest eGFP receptor expression had an 
increase in mRFP fluorescence of only 6,000 (a.u.) after incubation with targeted 
Connectosomes.  However, for the group of target cells with the highest eGFP receptor 
expression, the increase in mRFP fluorescence after addition of the targeted 
Connectosomes was 65,000 (a.u.). Further, as the eGFP receptor expression increases, the 
increase in mRFP fluorescence begins to plateau, indicating that the binding is saturated, 
and perhaps suggesting that if more targeted Connectosomes were added to the cells the 
mRFP fluorescence for group with the highest eGFP receptor expression would increase 
further (Figure 3.4e).
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Figure 3.4: Targeted Connectosome binding is correlated with eGFP receptor expression. (a), 
Example scatterplot from flow cytometry analysis showing the five gates used to analyze recipient target 
cells based on their eGFP receptor expression, as indicated by their eGFP fluorescence. (b) Average 
recipient cell eGFP fluorescence for each group. The error bars represent the standard deviations of 3 
independent trials, 5,000 total cells analyzed per trial. (c), Flow cytometry histograms showing mRFP 
fluorescence for each group of recipient target cells before (blue) and after (purple) incubation with 
extruded, targeted Connectosomes. Each curve represents 3 independent, concatenated trials, 5,000 total 
cells analyzed per trial. (d), Average increase in mRFP fluorescence after incubation with targeted 
Connectosomes for each cell group. The error bars represent the standard deviations of 3 independent trials, 
5,000 total cells analyzed per trial. (e), Targeted Connectosome binding as a function of GFP receptor 
expression. 
Next, to confirm the binding selectivity of the targeted Connectosomes, we 
completed a competitive binding study. Specifically, confluent monolayers of recipient 
target and off-target cells co-cultured in the same dish were incubated with targeted 
Connectosomes at the same concentration as the above experiments. After incubation, the 
recipient cells were washed to remove unbound vesicles, and binding was quantified 
using flow cytometry (Figure 3.5a-d). Target cells were separated from off-target cells 
based on their eGFP fluorescence intensity, so that binding for each cell type could be 
analyzed separately (Figure 3.5a). As expected, the average mRFP fluorescence of off-
target cells increased slightly, by less than 2,000 (a.u.) (Figure 3.5b-d). However, the 
average mRFP fluorescence of target cells increased dramatically, by almost 50,000 (a.u.) 
(Figure 3.5b-d). Interestingly, this data illustrates that in a competitive scenario, targeting 
selectively enhances Connectosome binding to target cells by nearly 30 times, almost 
triple the extent to which targeting enhances binding when the target and off-target cells 
are cultured separately as in the previous experiment. This finding implies that the 
interactions of Connectosomes with cells maybe somewhat transient, and that 
Connectosomes likely sample the surfaces of multiple cells in order to find the ones to 
which they bind most strongly.
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Figure 3.5: Targeted Connectosomes bound selectively to target cells. (a) Flow cytometry histogram 
showing eGFP fluorescence for co-cultured target and off-target cells. Gates shown were used to analyze 
each group of cells separately. The curve represents 3 independent, concatenated trials, 2,000 total cells 
analyzed per trial. (b), Flow cytometry histograms showing mRFP fluorescence for recipient off-target cells 
before (blue) and after (purple) incubation with extruded, targeted Connectosomes (left) and for recipient 
target cells (right) before (blue) and after (purple) incubation with extruded, targeted Connectosomes. Each 
curve represents 3 independent, concatenated trials, 2,000 cells analyzed per trial. (c), Average recipient 
cell mRFP fluorescence for each condition. The error bars represent the standard deviations of 3 
independent trials, 2,000 cells analyzed per trial. (d), Average increase in mRFP fluorescence for off-target 
and target cells after incubation with targeted Connectosomes. The error bars represent the standard 
deviations of 3 independent trials, 2,000 cells analyzed per trial. Legend in (b) applies to (c) and (d). 
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Targeting selectively enhanced cytoplasmic dye delivery to target cells 
 Having established the selectivity of targeted Connectosome binding, we next 
investigated how enhanced target cell binding affects molecular delivery (Figure 3.6). 
Specifically, targeted Connectosomes were loaded with calcein red orange (CRO) dye 
using established protocols1. Briefly, donor cells were treated with CRO-acetomethoxy 
(CRO-AM) dye prior to Connectosome production.  The AM group renders the CRO-
AM dye membrane permeable, but as the CRO-AM dye accumulates in the cytoplasm, 
the AM group is metabolized by intracellular esterases. The resulting CRO dye is 
membrane impermeable, and therefore trapped in the cytoplasm and permeable only to 
gap junctions36. Previous studies using untargeted Connectosomes to deliver CRO dye to 
cells established that delivery was both cytoplasmic and gap junction-dependent1. In 
particular, dye transfer was significantly reduced when cells were treated with 
carbenoxolone, a gap junction inhibitor37 that prevents junctions from forming between 
Connectosomes and cells,  before incubation with dye-loaded Connectosomes. 
Therefore, to demonstrate the ability of targeting to enhance selective delivery of 
molecular cargo to the cytoplasm, we conducted a competitive dye delivery study (Figure 
3.6). Specifically, confluent monolayers of co-cultured recipient target and off-target 
cells were incubated with either targeted or untargeted Connectosomes. Dye delivery was 
quantified by using flow cytometry to measure the increase in mRFP fluorescence after a 
45-minute incubation with the vesicles. Target cells were separated from off-target cells 
based on their eGFP fluorescence intensity, so that delivery for each cell type could be 
analyzed separately (Figure 3.6a). There was no significant difference in the increase in 
the average mRFP fluorescence for both target and off-target cells treated with untargeted 
Connectosomes, or for target cells treated with untargeted Connectosomes (Figure 3.6b-
e). However, the average mRFP fluorescence for target cells incubated with targeted 
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Connectosomes increased by 27,000, a nearly five-fold increase in delivery compared to 
untargeted Connectosomes. This data illustrates the ability of targeting to enhance 
selective delivery of molecular cargo to the cytoplasm of specific populations of target 
cells.
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Figure 3.6:  Continued on next page. 
 87 
Figure 3.6: Targeting enhances dye delivery to the cellular cytoplasm. (a), Flow cytometry 
histogram showing eGFP fluorescence for co-cultured target and off-target cells. Gates shown were used to 
analyze each group of cells separately. The curve represents 3 independent, concatenated trials, 2,000 total 
cells analyzed per trial. (b), Flow cytometry histograms showing mRFP fluorescence for recipient off-target 
cells before (blue) and after incubation with either untargeted (green) or targeted (purple) Connectosomes. 
Each curve represents 3 independent, concatenated trials, 2,000 cells analyzed per trial. (c), Flow cytometry 
histograms showing mRFP fluorescence for recipient target cells before (blue) and after incubation with 
either untargeted (green) or targeted (purple) Connectosomes. Each curve represents 3 independent, 
concatenated trials, 2,000 cells analyzed per trial. (d), Average recipient cell mRFP fluorescence for each 
condition. The error bars represent the standard deviations of 3 independent trials, 2,000 cells analyzed per 
trial. (e), Average increase in mRFP fluorescence after incubation with either untargeted or targeted 
Connectosomes for off-target and target cells. The error bars represent the standard deviations of 3 
independent trials, 2,000 cells analyzed per trial. Legend in (b) applies to (c) and (d). 
Targeted Connectosomes selectively delivered chemotherapeutics to target cells 
Having established the ability of targeting to enhance the selective delivery of 
molecular cargo to the cytoplasm, we then sought to understand the effects of targeting 
on the delivery and efficacy of the chemotherapeutic drug doxorubicin.  Previously, 
untargeted Connectosomes were used to reduce the therapeutically effective dose of this 
drug by more than an order of magnitude compared to free doxorubicin, and by several 
orders of magnitude compared to conventional liposomal doxorubicin1. However, we 
wanted to test whether targeting would simultaneously enable the selectivity of delivery 
while also enhancing the efficacy of delivery to target cells. 
We formed doxorubicin-loaded targeted Connectosomes by extruding 
unprocessed Connectosomes in cell media containing 300 µM doxorubicin using a 1 µm 
filter. The loaded, extruded, targeted Connectosomes were pelleted and washed to 
remove the unencapsulated doxorubicin. Then, the Connectosomes were resuspended in 
fresh media, and their doxorubicin content was quantified using established protocols1 
based on measuring the doxorubicin fluorescence emission of the vesicles. The targeted 
Connectosomes were then incubated with co-cultured target and off-target cells at 
equivalent doxorubicin doses increasing from 125 nM to 500 nM. After two hours, the 
Connectosomes were washed away. After 24 hours, cell viability was measured using a 
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7AAD viability stain (Figure 3.7a-c). As expected, for both target and off-target cells, the 
viability decreased with increasing doxorubicin dose. However, we found that at each 
equivalent doxorubicin dose, target cells were significantly less viable than off-target 
cells. For example, at 250 nM doxorubicin, only 3% of off-target cells were nonviable, 
while almost 23% of target cells were nonviable. Further, at 500 nM doxorubicin, only 
9% of off-target cells were nonviable, while target cells were more than six times less 
viable, at 62% nonviable. 
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Figure 3.7: Targeted Connectosomes enhance doxorubicin delivery to target cells. (a), Percentage 
of nonviable off-target cells(light purple) and nonviable target cells (dark purple) treatment with 
doxorubicin-loaded targeted Connectosomes. All points were measured using a 7-AAD viability assay, 
except for the 500 nM point, which was measured using a trypan blue viability assay. The error bars 
represent the standard deviations of 3 independent trials, 1,000 cells analyzed per trial. (b), Brightfield and 
fluorescence image showing that most dead cells are target cells. (c), Doxorubicin delivery to target and 
off-target cells after treatment with targeted Connectosomes at an equivalent doxorubicin dose of 250 nM, 
based on average doxorubicin fluorescence. The error bars represent the standard deviations of 3 
independent trials, 1,000 cells analyzed per trial. Legend in (a) applies to (c). Scale bar 250 µm. 
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To verify that this increase in nonviability was due to increased doxorubicin 
delivery to target cells, we examined the increase in doxorubicin fluorescence for both 
target and off-target cells after treatment with targeted Connectosomes (Figure 3.7b). We 
found that at each equivalent doxorubicin dose, significantly more doxorubicin was 
delivered to the target cells than to the off-target cells, confirming that the enhanced 
efficacy of treatment with targeted Connectosomes is indeed due to increased 
doxorubicin delivery. 
It is important to note that the increase in therapeutic efficacy observed for target 
cells is not necessarily expected to precisely match the increase in doxorubicin delivery 
to target cells, due to the fact that the bystander effect promotes transfer of drugs between 
cells. Specifically, cells that receive doxorubicin from targeted Connectosomes may 
transfer some doxorubicin to neighboring cells through gap junctions, perhaps increasing 
the therapeutic efficacy beyond the extent to which doxorubicin delivery itself was 
increased. Further, increased doxorubicin delivery may enhance the effects of the 
bystander effect. Additionally, the factor by which targeting increased the delivery of 
doxorubicin is not expected to precisely match the factor by which targeting increased in 
delivery of dye as discussed in Figure 3.6, due to the differences in timescales of these 
experiments, as well as differences in transport rates of these molecules through gap 
junctions. 
From this data, the therapeutically effective dose (LD50) of targeted 
Connectosomes for off-target cells can be estimated to be greater than 600 nM. While 
previous studies using untargeted Connectosomes to deliver doxorubicin to HeLa cells 
estimate the LD50 for this treatment to be around 500 nM1, the small difference we report 
here is expected due to the fact that extruded Connectosomes were used for the current 
studies, while intact Connectosomes were used for the previous studies. Extrusion is 
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expected to increase the LD50 of particles by reducing gravitational settling27, which 
results in reduced non-specific interactions with cells 
However, the LD50 for target cells was approximately 300 nM, demonstrating 
that targeting selectively increases the efficacy of chemotherapeutic delivery to target 
cells by approximately two-fold. This data demonstrates that targeting further reduces the 
LD50 of doxorubicin-loaded Connectosomes to a concentration that is more than an order 
of magnitude lower than the LD50 for free doxorubicin, which is approximately 10 µM1, 
and more than several orders of magnitude lower than the LD50 for conventional 
liposomal doxorubicin, which is greater than 1 mM1. In sum, these findings demonstrate 
the ability of targeting to selectively enhance the therapeutic efficacy of doxorubicin 
delivery via Connectosomes to specific populations of cells while protecting off-target 
cells cultured in the same dish, removing the limitations of non-specificity restricting the 
therapeutic potential of gap junction-based drug delivery strategies. 
Conclusion 
Connectosomes were previously established as promising therapeutic materials 
capable of efficiently transporting therapeutics to the cytoplasm through gap junctions1. 
These materials reduced the LD50 of doxorubicin by an order of magnitude compared to 
free doxorubicin, and by several orders of magnitude compared to conventional 
liposomal doxorubicin. However, their translational relevance was limited by the inherent 
lack of specificity in gap junction-based delivery approaches. Towards addressing this 
issue, here we report the development of targeted Connectosomes, cell-derived particles 
that use gap junctions and targeting proteins to selectively transport molecular cargoes to 
the cytoplasm of specific populations of cells.  
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Incorporating targeting proteins into Connectosomes selectively enhanced binding 
to target cells by 30 times compared to off-target cells, which is comparable to increases 
in binding exhibited by synthetic targeted particles12. Further, our data demonstrated that 
targeting selectively enhanced delivery of both dyes and drugs to target cells. In 
particular, targeting reduced the therapeutically effective dose of doxorubicin-loaded 
Connectosomes for target cells by 2 times compared to off-target cells, a similar increase 
in therapeutic efficacy compared to other targeting strategies38. In sum, this data 
demonstrates that harnessing the cell’s machinery to display multi-functional targeting 
molecules on the surfaces of cell-derived membrane particles is a promising strategy for 
overcoming issues of non-specific therapeutic delivery by Connectosomes. 
Further, our multi-functional targeting approach enables the incorporation of 
desirable features into the targeting protein, which may be difficult to include through 
chemical conjugation or other synthetic targeting strategies. For example, our approach 
could allow for incorporation of multiple, distinct targeting ligands in the targeting 
protein, in order to enable targeting of multiple receptors. Increasing the specificity and 
sophistication of the targeting system in this way could be useful for addressing challenge 
of delivery to heterogeneous tumors39. 
Ultimately, the development of a chemotherapeutic delivery system that both 
efficiently and selectively kills diseased cells represents a critical step towards realizing 
the therapeutic potential of Connectosomes and other particles which employ gap 
junctions for delivery. In the future, our targeting strategy could be utilized to target 
Connectosomes to a broad range of cell types. In this way, targeted Connectosomes could 
be used to deliver a range of membrane impermeable drugs and reagents, such as siRNA, 
peptides, and other macromolecules, to diverse populations of target cells. 
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Materials and Methods 
Plasmid constructs. The Tf-RΔEcto-mRFP AP180 CTD plasmid was first 
constructed by excising eGFP from the Tf-RΔEcto-eGFP AP180 CTD plasmid above 
with BamH1 and SalI digestion and inserting the PCR amplified mRFP (Addgene 
plasmid #13032, pcDNA3 backbone), a generous gift from Dr. Douglas Golenbock 
(University of Massachusetts Medical School). The pOPINE GFP nanobody sequence, a 
gift from Brett Collins (Addgene plasmid #49172), was PCR amplified and restriction 
cloned into Tf-RΔEcto-mRFP AP180 CTD using primers containing MluI sites. All 
constructs were confirmed by DNA sequencing.  
The chimaeric Tf-RΔEcto-GFP (GFP cargo) was made by modifying the Tf-R-
GFP construct (pEGFP-N1 backbone), kindly provided by Dr Tomas Kirchhausen 
(Harvard medical school), where the entire Tf-R sequence was excised by digesting with 
EcoRI and BamHI, and inserting only the PCR amplified intracellular and 
transmembrane domains of Tf-R adjacent to the GFP fluorophore with EcoRI and BamHI 
sites. An intermediate construct lacking a stop codon was made by digesting Tf-RΔEcto-
GFP with BamHI and NotI to remove GFP, and inserting a mutated PCR amplified GFP 
with the stop codon (TAA) replaced by a glycine (GGA).  
Stable cell line production. The GFP expressing HeLa cells were produced via 
lentiviral transfection. The GFP-tagged receptor gene sequence was subcloned onto 
pLJM1 viral transfer vector (addgene #19319) with NheI and EcoRI sites. Lentiviruses 
were generated by co-transfecting the transfer plasmid, packaging plasmid Δ8.9 and the 
envelope plasmid VSVG into 293T packaging cells with FuGENE. 48 hours after the 
transfection, virus-containing supernatant was collected, filtered and added to HeLa cells 
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with 8 ug/mL of polybrene. Transduced HeLa cells were selected with 2 ug/mL 
puromycin for 7 days.  
eGFP purification. The pRSET vector containing the nondimeriz- able hexa-his-
tagged eGFP (hisGFP A206K) was generously shared by Dr. Adam Arkin (University of 
California, Berkeley). Following published purification protocols40, 41, his-eGFP was 
expressed in BL21(DE3) pLysS cells overnight at 18 °C and purified from bacterial 
extracts by incubating with Ni-NTA agarose beads in 25 mM HEPES, 150 mM NaCl, 1 
mM imidazole, 1 mM β-mercaptoethanol, pH 7.4. After extensive washing with 25 mM 
HEPES, 150-300 mM NaCl, 1-5 mM imidazole, 1 mM β-mercaptoethanol, pH 7.4, 
proteins were eluted via a gradient imidazole wash to a final concentration of 250 mM. 
Eluted proteins were concentrated and dialyzed in 2 L 25 mM HEPES, 150 mM NaCl, 1 
mM EDTA, and 1 mM β-mercaptoethanol, pH 7.4, at 4 °C overnight and again for 2 h in 
fresh buffer at 4 °C. 
Targeting Protein Expression and Function. Soluble eGFP binding—HeLa cells 
stably expressing the GFPnb targeting protein were co-incubated with 250 nM soluble 
eGFP for 5 min at 37 °C, and then imaged. To test the expression and functionality of the 
GFPnb targeting protein, plasma membrane vesicles collected from the GFPnb cell line 
were incubated with 250 nM purified eGFP. Images were taken after 5 min of incubation 
at 37 °C. Expression and binding correlation analysis—A line was drawn across the 
GPMVs bound to soluble eGFP and the fluorescence intensity maximum in the eGFP and 
the mRFP channels were recorded. A total of 45 vesicles were analyzed with two distinct 
points per vesicle. All images were taken under the same camera settings.  
Binding studies. Off-target HeLa and/or target HeLa GFPr cells were plated in 96 
well plates at a density of 5,000 total cells per well. Targeted, intact Connectosomes were 
collected and extruded to 1.0 μm. The media was aspirated away from confluent cells and 
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the vesicles were added to the wells for 4 h at 37 °C. At the end of the incubation, 
recipient cell samples were then either imaged on the spinning disc confocal microscope 
or prepared for flow cytometry. To quantify the extent of binding, samples were prepared 
for flow cytometry analysis following established protocols1, 27. Briefly, cells were 
trypsinized and resuspended in 50 μL of PBS. 
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Chapter 4:  Quantifying the Ability of Clathrin to Sense Membrane 
Curvature 
Abstract 
Clathrin-mediated endocytosis is a primary pathway of entry into the cell that 
impacts diverse cellular processes, including growth, division, differentiation, and the 
internalization of nutrients and therapeutics. Therefore, understanding the fundamental 
molecular mechanisms that drive clathrin coat assembly is an important problem for both 
fundamental and applied research. Adaptor proteins, which bind to the membrane and to 
clathrin, are responsible for the biochemical recruitment of clathrin to endocytic 
structures. However, the physical cues that influence clathrin’s recruitment to the 
membrane remain debated. In particular, while some adaptor proteins, such as epsin and 
amphiphysin, bind preferentially to regions of high membrane curvature, it remains 
unknown whether clathrin itself possesses the ability to sense membrane curvature. To 
address this question, we isolated clathrin’s membrane curvature sensing ability in the 
absence of adaptor proteins by using recombinant, histidine-tagged clathrin that is 
engineered to bind directly to Ni-NTA-containing membranes. To examine clathrin 
binding to these membranes, we used a quantitative fluorescence intensity-based 
approach in which vesicles were tethered to a passivated surface and incubated with 
clathrin at specified concentrations. Using particle detection software and single-
molecule calibrations to determine the brightness of each vesicle and the brightness of the 
clathrin colocalized to each vesicle, we quantified the curvature of each individual vesicle 
as well as the corresponding number of bound clathrin triskelia. Our results demonstrate 
that clathrin binds preferentially to membranes of higher curvature. Specifically, when 
incubated with the same concentration of clathrin, vesicles with an average diameter of 
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25 nm recruited more than five times as many clathrin triskelia per membrane surface 
area in comparison to vesicles with an average diameter of 80 nm. This data was used to 
make a statistical model from which the curvature dependence of clathrin-lipid binding 
energy was extracted, providing fundamental insight into the process by which clathrin is 
recruited to highly curved membranes during clathrin-mediated endocytosis. 
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Introduction 
Clathrin-mediated endocytosis (CME) is a critical internalization pathway that 
eukaryotic cells rely upon in order for numerous physiological processes to occur1. For 
example, CME is one of the cell’s primary methods for plasma membrane receptor 
internalization2, 3. Cells also depend upon CME for the uptake of important nutrients, like 
cholesterol, iron, and other metabolites1. By controlling the uptake of these nutrients, as 
well as the composition of receptors at the plasma membrane, CME plays an important 
role in regulating signaling transduction and homeostasis, which in turn impacts a wide 
range of cellular functions, including growth, division, and differentiation4-7. 
Owing to clathrin-mediated endocytosis’ involvement in diverse cellular 
processes, defects in CME have been implicated in many diseases1. For example, 
impairments in CME have been associated with numerous cancers, including leukemia, 
lymphoma, and breast, ovarian, lung, and renal cancers. Mutations in some of the key 
proteins involved in CME have also been linked to various other diseases, including 
metabolic disorders such as diabetes, psychiatric disorders such as schizophrenia, and 
neurodegenerative disorders such as Alzheimer’s disease. Further, many nanoparticle-
based drug delivery strategies also rely upon clathrin-mediated endocytosis for drug 
uptake into the cell8. Therefore, understanding the molecular mechanisms that drive CME 
is an important biological problem relevant to fundamental fields, like cell biology and 
biophysics, as well as to applied fields, like biotechnology and pharmaceutics. 
During clathrin-mediated endocytosis, the plasma membrane is invaginated, 
forming a highly curved, clathrin-coated bud destined to separate from the plasma 
membrane and travel into the cytoplasm. This complex process of internalization can be 
broken into five distinct steps: (i) nucleation of the membrane bud, (ii) loading of the bud 
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with cargo destined for internalization, (iii) assembly of the clathrin coat, (iv) separation 
of the bud from the plasma membrane, and finally (v) uncoating of the trafficking 
vesicle1. For these steps to occur, a synchronized network of more than fifty distinct 
proteins is required9. For example, FCHO proteins, eps15, and intersectins are key 
players in bud nucleation10-12. Adaptor proteins including AP2, AP180, and epsin, as well 
as cargo-specific accessory adaptor proteins, help coordinate cargo loading and clathrin 
coat assembly13-16. Dynamin, a GTPase that is recruited to buds by proteins containing 
Bin/amphiphysin/Rvs (BAR) domains like amphiphysin and endophilin, is involved in 
vesicle scission, and vesicle uncoating is mediated by auxilin and heat shock cognate 70 
(HSC70)17-22. However, understanding precisely how these proteins interact to drive 
internalization remains a challenge.  
In particular, the physical cues that influence clathrin’s recruitment to the buds 
remain debated. Studies have demonstrated that several proteins involved in clathrin-
mediated endocytosis bind preferentially to regions of high membrane curvature, due to 
the presence of BAR domains and/or amphipathic helices in their structures23-25. In 
particular, BAR domains are thought to sense curvature due to their curved, crescent-like 
banana shape, while amphipathic helices are thought to sense curvature due to their 
enhanced insertion into membranes with lipid packing defects (these defects increase 
with increasing membrane curvature)23, 25. For example, the curvature sensing ability of 
the BAR domain of amphiphysin was first demonstrated using liposome sedimentation 
assays23. More recently, the curvature sensing ability of the amphipathic helices at the N-
termini of both amphiphysin and endophilin was demonstrated using fluorescence-based 
measurements on single liposomes24, and the curvature sensing ability of the amphipathic 
helix of epsin was demonstrated using fluorescence-based measurements on cylindrical 
liposome tethers and tubulation assays26, 27. In follow up studies, the curvature sensing 
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ability of these amphipathic helices was attributed to curvature-induced lipid-packing 
defects in membranes, which enable insertion of hydrophobic face of the amphipathic 
helices25.  
Once these proteins have assembled at highly curved membrane sites, they are 
able to recruit clathrin to these sites, which is thought to further reinforce curvature and 
drive bud formation. However, it remains unknown whether clathrin itself possesses the 
ability to sense membrane curvature and bind preferentially to curved structures. 
Therefore, understanding the inherent extent to which clathrin senses membrane 
curvature is important for furthering our fundamental understanding of the mechanisms 
that drive clathrin-mediated endocytosis. 
Results and Discussion 
Histidine-tagged clathrin bound to tethered vesicles 
To address this question, we isolated clathrin’s curvature sensing ability in the 
absence of adaptor proteins using recombinant, histidine-tagged clathrin triskelia that 
were engineered to bind directly to Ni-NTA-containing membranes28. Specifically, his-
tagged clathrin heavy chains were mixed with equimolar concentrations of untagged 
clathrin light-chains in order to form soluble, monodisperse triskelia. These triskelia are 
identical to clathrin triskelia prepared from bovine brain, and assemble into coats that are 
indistinguishable from those assembled with clathrin purified from bovine brain28. 
Further, the histidine tag on the N-terminus of clathrin heavy chain (near the 
physiological adaptor protein binding site) enables recruitment of clathrin triskelia 
directly to the surfaces of Ni-NTA-DOGS membranes, in the same orientation in which 
clathrin triskelia are recruited to biological membranes by adaptor proteins29, 30. 
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We began by designing an assay in which synthetic vesicles were tethered to a 
surface using biotin-neutravidin interactions (Figure 4.1a). Similar assays have been used 
previously to characterize the curvature sensing abilities of amphipathic helices and BAR 
domains, and are advantageous compared to bulk measurements on entire liposome 
populations because they permit measurements to occur on an individual liposome 
basis31-33. In our adaptation of this assay, glass slides were passivated using an 49:1 
mixture of PEG and PEG-biotin, in order to prevent non-specific binding, while also 
functionalizing the surface for tethering. Following incubation of neutravidin, vesicles 
containing biotinylated lipid were then added to the slides at a final lipid concentration of 
5 µM. In order to investigate curvature sensitivity, it was important to use vesicles that 
covered a range of diameters, from very highly curved vesicles roughly 30 nm in 
diameter, to vesicles roughly 200 nm in diameter, which are essentially planar, from the 
perspective of clathrin. This diameter range was achieved by tethering both sonicated and 
extruded vesicles. 
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Figure 4.1: Tethered vesicle assay allowed single liposome measurements. (a), Schematic 
illustrating the tethered vesicle assay. (b), Fluorescence image showing tethered vesicles (Oregon Green) 
and bound clathrin (Atto 594). (c-d), Using our approach, parameters including the number of bound 
clathrin triskelia (c) and the clathrin-to-lipid ratio (d) were calculated for a broad range of vesicle 
diameters. Each point represents a single vesicle. For these studies, vesicles were extruded using a 100 nm 
filter and incubated with 10 nM clathrin. Scale bar 2 µm. 
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Next, to examine the ability of clathrin to bind to these tethered vesicles, 10 nM 
histidine-tagged clathrin was incubated with the tethered vesicles. Assuming that one 
clathrin triskelion, which contains three his-tags, binds to nine Ni-NTA lipids, this 
concentration provided sufficient clathrin to fully coat the vesicles based on 
stoichiometry, yet is several orders of magnitude lower than the micromolar 
concentrations of triskelia required to drive the formation of lipid-free clathrin baskets in 
solution34. Fluorescence imaging of the tethered vesicles revealed colocalization of 
clathrin with the vesicles, indicating that the clathrin indeed bound the vesicles (Figure 
4.1b). 
To quantify binding of clathrin to the tethered vesicles, we used a quantitative 
fluorescence intensity-based approach. Specifically, we used fluorescence intensity 
calibrations to quantify various parameters for each vesicle, including the vesicle 
diameter, the number of clathrin triskelia bound to each vesicle, and the clathrin-to-lipid 
ratio for each vesicle. In particular, to quantify vesicle diameter, the fluorescence 
intensity of each vesicle was measured, and an average vesicle brightness for the 
population of vesicles was calculated. This average was then adjusted to match to the 
average diameter of the vesicles as reported by dynamic light scattering measurements. 
To quantify the number of clathrin triskelia bound to each vesicle, the fluorescence 
intensity of the clathrin bound to each vesicle was measured and then divided by the 
fluorescence intensity of a single, fluorescently-labeled clathrin triskelion under identical 
imaging conditions. Finally, to quantify the clathrin-to-lipid ratio for each vesicle, the 
number of lipids in each vesicle was calculated based on the vesicle diameter, and the 
number of clathrin triskelia bound to each vesicle was divided by the number of lipids in 
each vesicle to achieve the clathrin-to-lipid ratio. Using this approach, the number of 
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clathrin triskelia bound to each vesicle (Figure 4.1c), as well as the clathrin-to-lipid ratio 
for each vesicle (Figure 4.1d), were calculated for a broad range of vesicle diameters. 
Histidine-tagged clathrin assembled into coats on tethered vesicles 
Having established the ability of clathrin to bind to tethered vesicles, we next 
investigated whether clathrin could assemble into coats on tethered vesicles, as a means 
of verifying the functionality of our assay. To coat the vesicles, we employed two distinct 
assembly strategies. In the first method, a pH drop was used to drive assembly (Figure 
4.2a-b). Numerous studies have demonstrated that this is an effective method for driving 
clathrin assembly, due to the increased affinity of the clathrin triskelia for themselves at 
low pH2, 35-38. Specifically, the pH of the solution was dropped from pH 8.0 to pH 6.7 by 
adding 10% of 1M MES at pH 6.7 to the slides ten minutes after adding clathrin. The 
vesicles were imaged after 5 and 20 minutes at pH 6.7. For each time point, the number 
of triskelia and clathrin-to-lipid ratios were determined over a range of vesicle diameters 
as described above. As expected, the number of clathrin triskelia bound to each vesicle 
increased with increasing vesicle diameter, demonstrating the functionality of the assay 
under these conditions. Further, we observed clathrin-to-lipid ratios similar to those 
previously reported for complete clathrin coats, which are on average 3 triskelia bound 
per 1,000 lipids39. This agreement suggests that clathrin coat assembly was the 
predominant effect measured using this assay, as opposed to random clathrin aggregation. 
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Figure 4.2:  Continued on next page.
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Figure 4.2: Clathrin assembles into complete coats on tethered vesicles. (a), The number of clathrin 
triskelia bound increased when the pH was dropped, and reached the value expected for a complete coat 
based on previous literature reports. Each bar represents the average number of bound clathrin triskelia for 
vesicles analyzed. Error bars represent the standard deviation of at least 300 total vesicles analyzed for each 
condition. (b), The clathrin-to-lipid ratio reached the value expected for a complete coat when the pH was 
dropped. Each barrepresents the average clathrin-to-lipid ratio for vesicles analyzed. Error bars represent 
the standard deviation of at least 300 total vesicles analyzed for each condition. (c), The number of clathrin 
triskelia bound increased over time at constant pH, and reached the value expected for a complete coat. 
Each bar represents the average number of bound clathrin triskelia for vesicles analyzed. Error bars 
represent the standard deviation of at least 300 total vesicles analyzed for each condition. (d), The clathrin-
to-lipid ratio reached values expected for a complete coat after 90 minutes at constant pH. Each bar 
represents the average clathrin-to-lipid ratio for vesicles analyzed. Error bars represent the standard 
deviation of at least 300 total vesicles analyzed for each condition. (e), Negative stain transmission electron 
micrographs showing tethered vesicles coated in clathrin. For this study, vesicles were sonicated and 
incubated with 10 nM clathrin for 60 minutes. Scale bars 100 nm. 
However, lowering the pH to drive clathrin assembly was at times unreliable due 
to the increased tendency of clathrin to aggregate at low pH.  Therefore, we developed an 
alternative coating method which involved simply incubating clathrin with vesicles for 90 
minutes at pH 8.0 (Figure 4.2c-d). Using this assembly strategy, the number of clathrin 
triskelia bound to each vesicle, as well as the clathrin-to-lipid ratio for individual vesicles 
were quantified as described above. Again, the number of triskelia bound to each vesicle 
increased with increasing vesicle diameter, and clathrin-to-lipid ratios were consistent 
with previously reported values39, confirming that this second assembly approach was 
sufficient for coating the tethered vesicles.  
Finally, to further verify that clathrin assembled into coats on tethered vesicles, 
we used negative stain transmission electron microscopy to image the tethered vesicles 
after incubation with clathrin using the second assembly approach (Figure 4.2e). The 
vesicles appeared slightly flat, and, with diameters greater than 100 nm, were somewhat 
larger than expected, as vesicles with an average diameter of 50 nm were used for 
tethering. However, these discrepancies are perhaps due to the fact that the uranyl acetate 
negative stain can dehydrate and distort vesicles. Nonetheless, these images clearly depict 
the formation of clathrin lattices, and are similar in appearance to previously published 
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electron microscopy images of coated vesicles40. Therefore, formation of clathrin coats on 
vesicles verified that clathrin assembled on tethered vesicles. 
Histidine-tagged clathrin exhibited curvature sensitivity 
After establishing the ability of clathrin to assemble on tethered vesicles, we then 
sought to measure the preference of clathrin for highly curved membranes. Specifically, 
we sought to quantify the clathrin-to-lipid ratio for each vesicle as a function of vesicle 
diameter, in order to evaluate clathrin’s inherent curvature sensing ability. We repeated a 
binding assay similar to the one described above, at pH 8.0, this time incubating much 
lower concentrations of clathrin with the vesicles, in order to isolate clathrin’s curvature 
sensing ability from any cooperativity that might occur as assembly begins. 
Interestingly, our measurements of clathrin-to-lipid ratio suggested that clathrin 
binds preferentially to membranes of higher curvature (Figure 4.3a). Specifically, when 
incubated with the same concentration of clathrin in the same experimental well, larger 
clathrin-to-lipid ratios were achieved for vesicles with smaller diameters (and therefore 
higher curvatures). For example, vesicles with an average diameter of 25 nm recruited 
more than five times as many clathrin triskelia per membrane surface area in comparison 
to vesicles with an average diameter of 80 nm, indicating that clathrin triskelia have a 
similar intrinsic curvature sensing ability compared to previous reports measuring the 
curvature preference of the BAR domains and amphipathic helices of clathrin adaptor 
proteins24, 25.
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Figure 4.3: Clathrin exhibits curvature sensitivity. (a), The clathrin to lipid ratio increased with 
increasing vesicle curvature. For analysis, vesicles were divided equally into four cohorts based on 
diameter. Each point represents the average number of bound clathrin triskelia for vesicles within that 
cohort. Error bars represent the standard deviation for the vesicles within that cohort. At least 300 total 
vesicles analyzed for each condition. For this study, vesicles were sonicated and incubated with 100 pM 
clathrin. (b), Binding energy versus vesicle diameter. The change in binding energy decreased with vesicle 
curvature, demonstrating clathrin’s curvature sensing ability. 
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Curvature dependence of clathrin to vesicle binding energy 
Our data was input into a statistical model, from which the curvature dependence 
of clathrin to vesicle binding energy can be derived. Specifically, the probability of 
binding site occupancy as predicted by the Langmuir isotherm can be rearranged as 
follows to determine the change in energy that occurs when a triskelia binds to a vesicle:   𝑃!"#$% = !! 𝑒!!"#1 +  !! 𝑒!!"#  1 +  𝐿𝛺 𝑒!!"# ∗ 𝑃!"#$% = 𝐿𝛺 𝑒!!"#  
 𝑃!"#$% +  𝑃!"#$% ∗ 𝐿𝛺 𝑒!!"# = 𝐿𝛺 𝑒!!"#  
 𝐿𝛺 𝑒!!"# − 𝑃!"#$% ∗ 𝐿𝛺 𝑒!!"# = 𝑃!"#$%  
 𝑒!!"# 𝐿𝛺 − 𝑃!"#$% ∗ 𝐿𝛺 = 𝑃!"#$%  
 𝑒!!"# = 𝑃!"#$%!! − !!"#$%∗!!  𝛽𝛥𝛦 = ln 𝛺𝐿 𝑃!"#$%1 − 𝑃!"#$%  
Where PBOUND is the probability that an individual binding sites on the membrane 
surface is occupied by a clathrin triskelion, L is the number of clathrin triskelia available 
per binding site, and Ω is the total number of locations in solution where triskelia can 
reside prior to membrane binding. To determine the relationship between binding energy 
and curvature, our data were analyzed in eight separate cohorts based on vesicle diameter 
(inversely proportional to curvature). In particular, for each cohort, the average 
probability of binding was determined based on the average clathrin coverage of vesicles 
in each cohort. The total number of possible binding sites was determined based on the 
average vesicle surface area for each cohort and the number of vesicles within each 
cohort. Finally, the number of clathrin triskelia available for each binding site was 
determined based on the clathrin concentration and the size and density of tethered 
vesicles, which were constant across all cohorts. 
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Analyzing the data in diameter cohorts enabled determination of the relationship 
between binding energy and curvature, as plotted in Figure 4.3b. We found that the 
change in binding energy increased (negatively) with decreasing vesicle diameter (and 
therefore with increasing membrane curvature), a trend that is consistent with established 
curvature sensors and which suggests that it is more energetically favorable for clathrin to 
bind to highly curved membranes24, 25. Further, our data demonstrate that the free energy 
of the system is  more than 3 kBT lower per membrane-bound triskelia when triskelia 
bind to the most highly curved vesicles rather than to the largest, flattest vesicles. This 
change in binding energy is greater than the 1 kBT increase reported for amphipathic 
helices, suggesting that clathrin triskelia may possess a stronger preference for highly 
curved membranes than some of its adaptor proteins25. 
Conclusion 
In conclusion, we have evaluated the extent to which clathrin has the inherent 
capacity to sense membrane curvature. Our data demonstrated that clathrin binds 
preferentially to membranes of high curvature. Further, using the Boltzmann distribution, 
we have determined how the binding energy released as clathrin binds to vesicles 
depends on vesicle curvature. Our ongoing work continues to map the distribution of 
bound clathrin triskelia over vesicles with a range of different curvatures and to improve 
the statistical model from which the curvature dependence of binding energy can be 
derived. 
These findings provide fundamental insight into the process by which clathrin is 
recruited to highly curved membranes during clathrin-mediated endocytosis. In 
particular, it has previously been thought that only adaptor proteins sense curvature, 
while clathrin’s role is simply to concentrate coated vesicle components and drive 
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curvature1. However, our findings suggest that clathrin triskelia themselves are likely 
involved in sensing curvature. One possible role of clathrin as a curvature sensor could be 
to limit assembly of clathrin-coated vesicles only to groups of membrane-bound adaptor 
proteins located in regions of high membrane curvature. 
More broadly, our data suggests that the highly sequential model of clathrin-
coated vesicle assembly, in which adaptors arrive at membranes first and are then 
followed by clathrin1, could be over simplified. Specifically, our findings suggest that 
recruiting a critical nucleus of clathrin could be an early event that depends on membrane 
curvature. This speculation is consistent with the recent finding by the Kirchhausen lab, 
which was based on studies in live cells and showed that recruitment of clathrin is one of 
the earliest events to occur in the formation of a clathrin-coated vesicle41. 
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Materials and Methods 
Chemical reagents. DTT (dithiothreitol), TRIS (2-Amino-2-(hydroxymethyl)-
1,3-propanediol), PLL (poly-L-lysine) and Atto 594 NHS-ester were purchased from 
Sigma-Aldrich. Neutravidin and Oregon Green 488-DHPE (Oregon Green 488 1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine) were purchased from Thermo Fisher 
Scientific. Amine-reactive mPEG-SVA (mPEG-succinimidyl valerate) and biotin-PEG-
SVA (both molecular weight 5,000 Da) were purchased from Laysan Bio (Arab, AL, 
USA). DP-EG10-biotin (dipalmitoyl-decaethylene glycol-biotin) was generously 
provided by Darryl Sasaki42. All other lipids were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA), including: DOGS-NTA-Ni (1,2-dioleoyl-sn-glycero-3-[(N-(5-
amino-1-carboxypentyl)iminodiacetic acid)succinyl], nickel salt) and DOPC (1,2-
dioleoyl-sn-glycero-3-phosphocholine). his-Clathrin was generously provided by Eileen 
Lafer. 
Protein labeling. Protein labeling reactions were performed in 25 mM HEPES, 
150 mM NaCl, 1 mM TCEP, pH 7.2 buffer. Proteins were labeled using amine-reactive, 
NHS ester-functionalized dyes (Atto-Tec). The concentration of dye was adjusted 
experimentally to obtain the desired labeling ratio of 1:1. Reactions were performed for 
20 min at room temperature, labeled protein was separated from unconjugated dye via 
size exclusion chromatography with Sephadex G-25 (GE Healthcare Life Sciences). 
Fluorescence microscopy. A spinning disc confocal microscope (Zeiss Axio 
Observer Z1 with Yokagawa CSU-X1M) was used to image tethered vesicles. Laser 
wavelengths of 488 and 561 nm were used for excitation. Emission filters were centered 
at 525 nm with a 50-nm width, and 629 nm with a 62-nm width. A triple-pass dichroic 
mirror was used: 405/488/561 nm. The microscope objective used was a Plan-
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Apochromat 100x, 1.4 numerical aperture oil immersion objective. Tethered vesicles 
were imaged on an EMCCD camera. 
Liposome preparation. Vesicles were composed of 95.5 mol% DOPC, 2 mol% 
DOGS-NTA-Ni, 0.5 mol% Oregon Green 488-DHPE, and 2 mol% DP-EG10-biotin. 
Dried lipid films were hydrated in storage buffer (10 mM TRIS, 25mM BME, pH 8.0) 
and either sonicated or extruded to 100 nm. 
Tethered vesicle assay. Biotinylated PLL-PEG was made according to a previous 
protocol (Ruiz Taylor 2001). Briefly, amine-reactive PEG and PEG-biotin was added to a 
40 mg mL-1 mixture of PLL in 50 mM sodium tetraborate, pH 8.5, at a stoichiometric 
ratio of one PEG per five lysine subunits. PEG-biotin comprised either 2% of the total 
PEG amount. The mixture was stirred continuously for 6 h at room temperature, and 
subsequently buffer exchanged into PBS using Centri-Spin size exclusion columns 
(Princeton Separations).  
Imaging wells were made by placing silicone gaskets onto ultraclean coverslips. 
Wells were coated for 1 h with biotinylated PLL-PEG that was diluted tenfold in 
experiment buffer (10 mM TRIS, 25 mM BME, 25 mM KCL, pH 8.0). After coating, the 
well was washed repeatedly with experiment buffer to wash out excess PLL-PEG. 
Neutravidin was then added to the well at a final concentration of 0.2 mg mL-1, incubated 
for 10 min, and the well was repeatedly washed with experiment buffer. 
Vesicles were then diluted to 5 µM in the imaging wells and allowed to tether to 
the substrate for 10 min. Untethered vesicles were removed by thorough washing of the 
well with experiment buffer. The same laser power and camera gain settings were used 
for all experiments 
Determination of parameters from vesicle and protein brightness 
measurements. All images in the z-stacks were cropped to the center 171x171 pixels, and 
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the frame with the greatest mean brightness was selected for analysis. Fluorescence 
amplitudes of diffraction-limited puncta were obtained using cmeAnalysis particle 
detection software (Aguet 2013). Individual vesicles were detected by fitting two 
dimensional Gaussian profiles to each puncta in the lipid fluorescence channel. The 
standard deviation of the Gaussian was determined from the point spread function of our 
microscope. The brightnesses of detected puncta were reported as valid if they were 
diffraction-limited and had amplitudes significantly above their local fluorescence 
background. The program then used the centroids of the lipid fluorescent puncta to check 
for fluorescent puncta near the centroid in the protein fluorescence channel. To further 
ensure that only legitimate puncta were analyzed, we only accepted puncta whose 
amplitude was greater than two standard deviations above the average of all the local 
fluorescence background values measured for each detected puncta in the image. 
We estimated vesicle size from lipid fluorescence brightness values by computing 
a scaling factor which centered the mean of the vesicle brightness distribution, prior to 
adding protein, to the intensity-weighted average vesicle size obtained from dynamic 
light scattering.  
We estimated the number of bound proteins on each vesicle by comparing 
brightness values in the protein channel to the known brightness of a single molecule of 
his-Clathrin-Atto 594. Images of single molecules of his-Clathrin-Atto 594 were obtained 
by adding a dilute concentration of protein to an imaging well on an ultraclean coverslip, 
and imaging in a similar manner as described for the tethered vesicles. A longer camera 
exposure time was necessary to image single molecules. A linear correction for exposure 
time was therefore applied to the single molecule brightness value before comparing with 
brightnesses of membrane-bound protein. 
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Electron microscopy. Vesicles for electron microscopy were tethered directly 
onto glow-discharged, 300 square mesh, carbon-coated grids and stained with 2% uranyl 
acetate (Electron Microscopy Sciences; Hatfield, PA, USA). Images were collected on a 
Tecnai Spirit BioTwin T12 electron microscope (Tecnai; Hillsboro, OR, USA). 
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Chapter 5:  Conclusion 
Ultimately, in my thesis work I have addressed both the need to (i) introduce new 
methods of therapeutic delivery that overcome the limitations of existing mechanisms, 
and the need to (ii) understand the existing mechanisms of therapeutic uptake at a 
molecular level.  
Towards introducing new methods of therapeutic delivery that overcome the 
limitations of existing mechanisms, I have developed targeted Connectosomes, cell-
derived lipid vesicle materials that contain embedded connexons and are capable of 
forming functional gap junctions with cells. By opening direct routes to the cytoplasm, 
these materials reduced the therapeutically effective dose (LD50) of doxorubicin for 
target cells by more than an order of magnitude in comparison to the unencapsulated 
drug, and by several orders of magnitude in comparison to conventional liposomal 
doxorubicin. Further, through interactions of embedded multi-functional, multi-domain 
transmembrane targeting proteins that target cell-specific receptors, these materials 
achieved targeted delivery of molecular cargo directly into the cytoplasm of specific 
populations of target cells.  
Illustrating the therapeutic importance of direct access to the cell cytoplasm, my 
work in this area represents a key step towards achieving efficient therapeutic delivery 
independently of endocytosis. In the future, targeted Connectosomes could be used to 
increase the effectiveness of diverse therapeutics. Likely next steps for the 
Connectosomes include adapting the technology to facilitate delivery of diverse, 
membrane impermeable therapeutics, including siRNA and peptides. Additionally, in 
order to realize the translational potential of the Connectosomes, many steps must also be 
taken in order to scale-up production of these materials, and to characterize their in vivo 
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behaviors such as circulation time, tumor penetration, and stability. While there are still 
many challenges to overcome, the contribution of my work has been to inspire the field 
by highlighting the potential of gap junctions as delivery route that is entirely untapped 
by current therapeutics. 
Towards furthering our fundamental understanding of the mechanisms of 
therapeutic uptake at the molecular level, I have also investigated the curvature sensing 
abilities of clathrin, a key protein involved in clathrin-mediated endocytosis. In particular, 
my findings demonstrate that clathrin binds preferentially to highly curved membranes. 
Although it has previously been thought that clathrin is involved only in the later stages 
of endocytosis, my results demonstrate clathrin’s inherent curvature-sensing ability and 
suggest a possible explanation for clathrin’s early participation in endocytic vesicle 
formation. Therefore, my work in this field represents a key step in furthering our basic 
biophysical understanding of the mechanisms that drive clathrin-mediated internalization 
of nanoparticles and other molecular cargo. 
In sum, this work represents key steps towards improving the success of 
nanoparticle-based drug delivery strategies from both applied and fundamental 
standpoints. 
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